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ACKGROUND: Obesity is a growing threat to 
global health by virtue of its association with 
insulin resistance, inﬂammation, hypertension, 
and dyslipidemia, collectively known as the metabolic 
syndrome (MetS). The nuclear receptors PPAR  and 
PPAR  are therapeutic targets for hypertriglyceridemia 
and insulin resistance, respectively, and drugs that 
modulate these receptors are currently in clinical use. 
More recent work on the PPAR  has uncovered a dual 
beneﬁt for both hypertriglyceridemia and insulin 
resistance, highlighting the broad potential of PPARs 
in the treatment of metabolic disease.
CONTENT: We have learned much about PPARs, the 
metabolic fat sensors, and the molecular pathways they 
regulate. Through their distinct tissue distribution and 
speciﬁc target gene activation, the three PPARs together 
control diverse aspects of fatty acid metabolism, energy 
balance, insulin sensitivity glucose homeostasis, 
inﬂammation, hypertension and atherosclerosis. 
These studies have advanced our understanding of 
the etiology for the MetS. Mechanisms revealed by 
these studies highlight the importance of emerging 
concepts, such as the endocrine function of adipose 
tissue, tissue-tissue cross-talk and lipotoxicity, in the 
pathogenesis of type 2 diabetes mellitus and CVD.
SUMMARY: The elucidation of key regulators 
of energy balance and insulin signaling have 
revolutionized our understanding of fat and sugar 
Abstract
metabolism and their intimate link. The three ‘lipid-
sensing’ (PPAR , PPAR  and PPAR ) exemplify 
this connection, regulating diverse aspects of lipid 
and glucose homeostasis, and serving as bonaﬁde 
therapeutic targets.
KEYWORDS: Peroxisome Proliferator, Activated 
Receptor, Metabolic Syndrome.
Introduction
The metabolic syndrome, is characterized by abdominal 
obesity, atherogenic dyslipidemia, hypertension, 
insulin resistance, inﬂammation, and prothrombotic 
states (1).
The major sequelae are cardiovascular disease 
and type 2 diabetes mellitus, but the syndrome also 
increases the risk of polycystic ovary syndrome, fatty 
liver, cholesterol gallstones, asthma, sleep disturbances, 
and some forms of cancer (2). The pathogenesis of the 
MetS is thought to involve a complex interaction of 
multiple factors, which include obesity and abnormal 
fat distribution; insulin resistance; hepatic, vascular, 
and immunologic factors; and lifestyle and genetic 
contributions (3).
Recent advances in our understanding of adipose 
tissue biology and, in particular, its endocrine function 
and the dysregulated state associated with obesity 
characterized by enlarged adipose cells have provided 
insight into the mechanisms involved (4).
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Increased adipose tissue mass contributes to 
augmented secretion of proinﬂammatory adipokines, 
particularly tumor necrosis factor-  (TNF ), along with 
diminished secretion of the “protective” adiponectin. 
TNF  and adiponectin are antagonistic in stimulating 
nuclear transcription factor- B (NF- B) activation. 
Through this activation, TNF  induces oxidative stress, 
which exacerbates pathological processes leading to 
oxidized low-density lipoprotein and dyslipidemia, 
glucose intolerance, insulin resistance, hypertension, 
endothelial dysfunction, and atherogenesis. Elevated 
free fatty acid, glucose, and insulin levels enhance this 
NF- B activation and further downstream modulate 
speciﬁc clinical manifestations of metabolic syndrome 
(5).
Although there has been a debate on the criteria 
and concept of the metabolic syndrome, the current 
deﬁnition by the National Cholesterol Education 
Program–Adult Treatment Panel (NCEP-ATP III) 
and the International Diabetes Federation (IDF) 
provide adequate screening tools to identify the 
subjects with high cardiometabolic risk. With these 
tools in hand the stage is set for attempts to discover 
the pathophysiology underlying these metabolic 
abnormalities. The identiﬁcation of intracellular 
signaling elements and regulating factors at crossroad 
steps that direct the metabolic fate of lipids are critical 
for the understanding of atherogenic dyslipidemia 
in the MetS. Importantly, several lipid metabolites 
seem to play a crucial role in the regulation of insulin 
signaling and action inﬂuencing endothelial function 
and initiating vascular injury. The concept that 
dysfunctional adipose tissue cannot properly handle 
the energy surplus derived from excessive calorie 
consumption combined with sedentary lifestyle sets 
the stage to identify the main determinants of the 
MetS in different populations. Resolving these issues 
is crucial for the optimal management of the MetS and 
reduction of global CVD risk (6).
Peroxisome proliferator-activated receptor 
(PPAR)s are a family of 3 (PPAR , / , and ) nuclear 
receptor/ligand-activated transcription factors that 
work in concert as heterodimers with the retinoid 
X receptors (7). In recent years, there has been great 
scientiﬁc and clinical interest in the actions of PPAR  
and PPAR  because they are the molecular targets 
for the clinically used lipid-lowering ﬁbrates and 
insulin-sensitizing thiazolidinedione classes of drugs, 
respectively (7,8).
The recent development of highly selective 
ligands and PPAR /  knockout and transgenic mice, 
however, have now implicated roles for PPAR /  in 
adipose tissue formation, metabolism, wound healing, 
brain development, placental function, colorectal 
carcinogenesis, and skeletal muscle function. PPAR /
 ligands appear highly effective in regulating lipid 
metabolism, particularly in skeletal muscle, and are 
currently in phase II clinical trials for treatment of 
dyslipidemia, aimed particularly at individuals with 
low HDL levels (9,10,11). All of the PPARs, therefore, 
appear to be able to target aspects of the MetS (11). 
Because the MetS represents a major risk factor for 
cardiovascular diseases, there has been an increasing 
interest in the roles of PPARs, in particular most recently 
PPAR / , in vascular biology. Indeed, in addition to 
the treatment of dyslipidemia, PPAR /  ligands may 
reduce the development in atherosclerosis (11,12). 
The discovery cycle involving nuclear receptors 
has elucidated the molecular and physiological basis 
for a new class of pharmacophores that show promise 
for treating the MetS (3).
The Biology of  PPARs
PPARs are members of the nuclear receptor 
superfamily which includes the steroid, retinoid, 
and thyroid hormone receptors. These receptors are 
transcription factors that regulate gene expression 
in response to certain endogenous and exogenous 
ligands. It is now well established that the PPARs act 
as central transcriptional mediators in the regulation 
of several important metabolic processes that 
inﬂuence adipogenesis, insulin sensitivity, glucose 
homeostasis, lipid metabolism, vascular endothelial 
function, atherosclerosis progression, and ultimately 
cardiovascular risk (13).
MOLECULAR BIOLOGY OF PPARS
The three PPARs are ligand-activated transcription 
factors of the nuclear hormone receptor superfamily. 
They share a high degree of structural homology 
with all members of the superfamily, particularly in 
the DNA-binding domain and ligand- and cofactor-
binding domain. Many cellular and systemic roles 
have been attributed to these receptors, reaching far 
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beyond the stimulation of peroxisome proliferation in 
rodents after which they were initially named. PPARs 
exhibit broad, isotype-speciﬁc tissue expression 
patterns (11).
PPAR  (NR1C1) (Nuclear Receptors Nomenclature 
Committee, 1999) was ﬁrst described as a receptor that 
is activated by peroxisome proliferators, hence its 
name (14). Two additional related isotypes, PPAR /
 (NR1C2) and PPAR  (NR1C3), were then found 
and characterized.The PPAR /  isotype was called 
PPAR when it was ﬁrst isolated from a Xenopus oocyte 
library (15). Because the mammalian PPAR protein 
sequence was not highly homologous to the Xenopus 
PPAR  protein sequences, it was named PPAR  when 
identiﬁed in the mouse with the view that there may 
be four members of this nuclear receptor family (16). 
PPAR  was also designated FAAR (fatty acid activated 
receptor) (17) in rats and NUC1 in humans (18). 
Sequencing of mammalian genomes indicated that 
there are only three PPAR isotypes. Characterization 
of PPARs in the chick and comparison with the 
PPARs of mouse and Xenopus demonstrated that the 
mammalian PPAR  is the ortholog of the amphibian 
PPAR  For reasons of clarity, we propose that this 
receptor be designated herein as PPAR /  (16).
PPAR  is expressed at high levels in organs that 
carry out signiﬁcant catabolism of fatty acids such 
as the brown adipose tissue, liver, heart, kidney, and 
intestine (19). Of the three isotypes, PPAR /  has 
the broadest expression pattern, and the levels of 
expression in certain tissues depend on the extent 
of cell proliferation and differentiation. Important 
functions have been assigned to this isotype in the 
skin, gut, placenta, skeletal muscle, adipose tissue, 
and brain (10,11,20,21,22). PPAR  is expressed as two 
isoforms, 1 and 2, that differ at their N terminus. 
PPAR 2 is found at high levels in the different adipose 
tissues (15,23,24), whereas PPAR 1 has a broader 
expression pattern that extends to settings such as the 
gut, brain, vascular cells, and speciﬁc kinds of immune 
and inﬂammatory cells (25,26).
PPARs requires heterodimerization with the 
retinoid X receptor (RXR; NR2B), which belongs 
to  the same receptor superfamily (27,28). This 
PPAR/RXR heterodimer can form in the absence of 
a ligand. When activated by a ligand, it modulates 
transcription  via binding to a speciﬁc DNA sequence 
element frequently called a peroxisome proliferator 
response element (PPRE) (15,27,29,30).  This response 
element, generally of the direct repeat 1 (DR-1) type, 
is composed of two half-sites that occur as a direct 
repetition of the consensus sequence AGGTCA with 
a single nucleotide spacing between the two repeats. 
The PPRE is usually present in one or multiple copies 
in the promoter region of target genes but may also be 
located in the proximal transcribed region of certain 
PPAR-responsive genes (31). PPAR and RXR bind to 
the 5’ and 3’ half-sites of this element, respectively, 
and the 5’-ﬂanking region mediates the selectivity of 
binding between different PPAR isotypes (32,33,34). 
Transcriptional control by PPAR/RXR heterodimers 
requires interaction with coregulator complexes—
either a coactivator for stimulation or a corepressor for 
inhibition of target gene expression (35,36,37,38).
Thus, selective action of PPARs in vivo results 
from the interplay at a given time point between 
expression levels of each of the three PPAR and RXR 
isotypes, afﬁnity for a speciﬁc promoter PPRE, and 
ligand and cofactor availabilities (11).
A wide variety of natural or synthetic compounds 
was identiﬁed as PPAR ligands. Among the synthetic 
ligands, the lipid – lowering drugs, ﬁbrates, and the 
insulin sensitizers, thiazolidinediones, are PPAR  and 
PPAR  agonists, respectively, which underscores the 
important role of PPARs as therapeutic targets (11).
The prevalent point of view today is that PPARs 
act as lipid sensors that translate changes in lipid/fatty 
acid levels from the diet or from food deprivation into 
metabolic activity, leading to either fatty acid catabolism 
or lipid storage. The endogenous ligands or mediators 
of these changes have not been characterized but are 
probably generated by fatty acid metabolism. Their 
activities are likely to be inﬂuenced by their binding 
speciﬁcities toward the different PPARs and by cell-, 
tissue-, or organ- speciﬁc effects (39,40,41).
The possible pathways that generate lipid 
mediators from fatty acids, which also serve as PPAR 
ligands, are recapitulated in Fig. 1. In addition, speciﬁc 
lipolytic pathways, for example the action of lipoprotein 
lipase and endothelial lipase, can hydrolyze certain 
circulating lipoproteins to generate PPAR ligands 
and PPAR activation (43,44,45). Given the variety and 
distribution pattern in the body of fatty acids and fatty 
acid derivatives with a wide range of afﬁnity to PPARs, 
it has been difﬁcult thus far to thoroughly evaluate the 
contribution of each of these endogenous ligands to the 
biology of PPARs. However, it is not surprising, based 
on the characteristics of these endogenous ligands 
with their broad spectrum of activation efﬁciency, that 
PPARs are involved in functions as diverse as lipid and 
carbohydrate metabolism, immune/inﬂammatory 
responses, vascular biology, tissue repair, and cell 
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differentiation and p roliferation. The d istribution 
and abundance of t he ligands a lso depend o n a 
variety o f pathophysiological situations a ssociated 
with hyperlipidemia, hypertension, diabetes, chronic 
inﬂammation, c ancer, and a therosclerosis. I t is 
important to note that some of these endogenous lipid 
mediators also signal through the classic cell surface 
G-protein-linked r eceptors and t herefore have m any 
PPAR-independent effects (11).
Fig. 1. Endogenous pathways for PPAR ligand production (Adapted from Michalik L, et al. 2006).
Among synthetic ligands, compounds of the ﬁbrate 
family (cloﬁbrate, f enoﬁbrate, and bezaﬁbrate) and 
their derivatives have been widely used to characterize 
PPAR  functions (43). Taken together, mouse models 
suggest that PPAR  functions to increase fatty-acid use 
in t he f asting state and t hat i n the pathophysiologic 
context o f a high-fat diet, PPAR -induced f atty-acid 
catabolism m ight p revent hypertriglyceridemia. 
Consistent with this prediction, an activated variant of 
PPAR  (Leu162Val) is associated with low serum TG 
levels and reduced adiposity (46).
PPAR  is expressed in adipocytes, macrophages, 
and m uscle, where it r egulates development, lipid 
homeostasis, and g lucose m etabolism. Endogenous 
PPAR  agonists i nclude f atty a cids and e icosanoids 
(47,48,49). The PPAR  genetic program includes target 
genes involved in the uptake of glucose in muscle (c-
Cbl associated protein and glucose transporter 4), lipid 
metabolism (scavenger receptor, adipocyte-fatty-acid–
binding protein, lipoprotein lipase, fatty-acid–binding 
protein, a cyl-CoA s ynthetase, and CYP4B1), and 
energy expenditure ( glycerol k inase and uncoupling 
proteins 2 and 3) (50,51,52,63,54,55,56,57,58).
In addition to r egulating glucose and lipid 
metabolism, PPAR  i s a potential modiﬁer o f 
atherogenesis. Signaling through PPAR , components 
of oxidized l ow-density lipoprotein ( LDL) i ncrease 
expression of the scavenger receptor CD36, resulting 
in lipid a ccumulation in m acrophages ( 59,60). 
PPAR also a ctivates t he m acrophage L XR-ABCA1 
cholesterol efﬂux pathway ( 61), which m ay explain 
8The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.4-31 Print ISSN: 2085-3297, Online ISSN: 2355-9179
the ﬁnding that PPAR  ligands inhibit the formation 
of a therosclerotic l esions i n LDL-receptor–deﬁcient 
mice (62).
The landmark ﬁnding that the thiazolidinedione 
class of insulin sensitizers, including rosiglitazone and 
pioglitazone, function as high-afﬁnity PPAR  agonists 
has validated t he e fﬁcacy o f PPAR  m odulation in 
treating the MetS (63).
PPAR  is expressed ubiquitously and is activated 
by f atty a cids and c omponents of very-low-density 
lipoprotein ( VLDL) (43,47). PPAR  t arget genes 
control  -oxidation in murine brown fat (long-chain 
and very-long-chain acyl-CoA s ynthetase, l ongchain 
and very-long-chain acyl-CoA dehydrogenase, and 
acyl-CoA oxidase), energy expenditure ( uncoupling 
proteins 1  and 3 ), and lipid storage ( macrophage 
adipose differentiation–related protein) ( 64,65). In 
the pathophysiological context o f a high-fat diet, 
PPAR  c ould function to i ncrease adipose fatty-acid 
catabolism and m ay p lay a role i n VLDL –  i nduced 
lipid a ccumulation in a therosclerotic f oam c ells. A  
high-afﬁnity synthetic PPAR  agonist has been shown 
to i ncrease HDL and decrease LDL, T G, and f asting 
insulin in obese rhesus monkeys. These studies suggest 
that therapeutic activation of PPAR  has the potential 
to decrease diet-induced obesity w ithout a ctivating 
the PPAR  dependent adipogenic program (66).
PPARs AND CONTROL OF METABOLISM
Lipids a re e ssential for energy homeostasis, 
reproductive and o rgan physiology, and numerous 
aspects o f cellular biology. T hey a re a lso linked t o 
many pathological processes, such as obesity, diabetes, 
heart disease, and inﬂammation. To meet the different 
demands from a variety of tissues, the human body has 
evolved a  sophisticated lipoprotein transport system 
to deliver cholesterol and fatty acids to the periphery 
(Fig. 2) (67).
Fig. 2 Circulating lipoproteins deliver both energy substrates and endogenous activators for PPARs  (Adapted from Lee CH, et al, 2003).
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Disturbances in this system are integral components 
of lifethreatening diseases, best exempliﬁed by the 
metabolic syndrome, which refers to patients who 
are insulin-resistant (hyperinsulinemic), dyslipidemic 
(elevated TG and decreased HDLC levels) (68).
Lipids and their derivatives have a role in the 
genetic control of their own systemic transport, 
cellular uptake, storage, mobilization, and use. Fine 
tuning of these metabolic processes is a hallmark of 
healthy organisms. Lipid homeostasis depends on 
factors that are able to transduce metabolic parameters 
into regulatory events representing the fundamental 
components of the general control system (69).
The identiﬁcation of fatty acids as endogenous 
ligands for PPARs has provided a unique approach to 
study lipid homeostasis at the molecular level (68).
Liver is the key site of metabolic integration 
where fatty acids are mobilized and, depending on 
the body’s needs, either stored or used as an energy 
source. In the fasting state, the fuel sources of the 
body shift from carbohydrates and fats to mostly fats, 
and fatty acids that were stored during feeding are 
released from the adipocyte and taken up by liver. 
There they are either reesteriﬁed to TGs and assembled 
into VLDL or broken down through -oxidation 
and used to generate ketone bodies. Earlier studies 
have demonstrated that in the liver, PPAR  directly 
regulates genes involved in fatty acid uptake [fatty 
acid binding protein (FABP)], -oxidation (acyl-CoA 
oxidase) and -oxidation (cytochrome P450). Gene 
targeting studies conﬁrmed that PPAR  is essential for 
the up-regulation of these genes caused by fasting or 
by pharmacological stimulation with synthetic ligands 
such as the ﬁbrates (70,71,72).
Fasting also results in severe hypoglycemia, 
hypoketonemia, and elevated plasma levels of 
nonesteriﬁed fatty acid, indicating a defect in fatty 
acid uptake and oxidation caused by dysregulation 
of these genes (73,74). In line with these observations, 
the ﬁbrate class of drugs including fenoﬁbrate and 
gemﬁbrozil, which are synthetic ligands for PPAR , 
lower serum TGs and slightly increase HDL cholesterol 
levels in patients with hyperlipidemia (75), most 
likely due to induction of fatty acid oxidation through 
activation of PPAR . PPAR  has also been shown to 
down-regulate apolipoprotein C-III, a protein which 
inhibits TG hydrolysis by LPL. This activity of PPAR  
ligands further contributes to the lipid-lowering effect 
(68). 
Apolipoprotein A-V (apoA-V) is now recognized 
as a key regulator of serum TG levels. Administration 
of the PPAR  agonist caused a 50% decrease in TG that 
reversed at washout. Serum apoA-V concentrations 
increased 2-fold, correlated inversely with TG, and 
were reversible at washout. The apoA-V/apoC-III 
ratio increased 2-fold, with this increase also reversible 
at washout. These data demonstrate for the ﬁrst time 
that a PPAR  agonist increases circulating apoA-V 
protein levels and the apoA-V/apoC-III ratio (76).
Unlike its function in the adaptive response 
to fasting, the role of PPAR  in cardiovascular 
pathogenesis appears to be detrimental. Cardiac-
speciﬁc PPAR  overexpression increases fatty acid 
oxidation and concomitantly decreases glucose 
transport and use, a phenotype similar to that of the 
diabetic heart, indicate that PPAR  senses fatty acids 
and induces their use, and thus plays a causative 
role in cardiomyopathy. The net effect, however, of 
ﬁbrate intervention in cardiovascular disease is likely 
beneﬁcial because systemic TG reduction should result 
in less fat accumulation in the heart and at the vessel 
wall (68).
Adipocytes are the main site for lipid storage 
and modulate the levels of lipids in the blood stream 
in response to hormonal signals. PPAR  has high 
expression in this tissue and has been shown to 
potentiate adipocyte differentiation from ﬁbroblasts 
(54). The PPAR 2 isoform prevents lipotoxicity by (a) 
promoting adipose tissue expansion, (b) increasing the 
lipid-buffering capacity of peripheral organs, and (c) 
facilitating the adaptive proliferative response of -
cells to insulin resistance (77).
PPAR  also promotes cholesterol efﬂux through 
the induction of a transcriptional cascade involving 
the nuclear sterol receptor LXR  and its downstream 
target ABCA1, a membrane transporter that is 
important for HDL-mediated reverse cholesterol 
transport (61,78,79,80). In this view, one would predict 
that in the absence of proportionately increased ox-
LDL, pharmacological activation of PPAR  should 
shift the balance from lipid loading to lipid efﬂux and 
improve the status of the atherosclerotic lesion (68).
PPAR  has recently been shown to mediate VLDL 
signaling in the macrophage (43). VLDL  treatment in 
cultured macrophages results in lipid accumulation 
and up-regulation of adipose differentiation-related 
protein, a lipid droplet-coating protein that has been 
implicated in lipid storage (81). Adipose differentiation-
related protein was subsequently identiﬁed as a direct 
PPAR  target gene, and components of VLDL released 
by LPL serve as ligands for the receptor (68).
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 Exercise increases fatty acid oxidation (FAO), 
improves serum HDLC and TG, and upregulates skeletal 
muscle PPARδ expression. In parallel, PPARδ agonist-
upregulated FAO would induce fatty-acid uptake (via 
peripheral lipolysis), and inluence HDLC and TG-rich 
lipoprotein particle metabolism, as suggested in preclinical 
models (8β). In their report, Oliver et al demonstrate that 
a selective PPARδ agonist increases ABCA1 expression 
and cholesterol eflux from cells and increases HDLC in 
primates. PPARδ agonists may provide a new approach 
to the treatment of cardiovascular disease by promoting 
reverse cholesterol transport (66).
 Molecular and functional analyses suggest that 
PPARδ activation reduces hepatic glucose output by 
increasing glycolysis and the pentose phosphate shunt and 
promoting fatty acid synthesis in the liver. This uncovered 
hepatic activity thus constitutes the earliest component 
of the regulatory mechanism by which PPARδ regulates 
insulin sensitivity, in addition to its known function in fatty 
acid ȕ-oxidation (8γ). 
 Coupling increased hepatic carbohydrate
catabolism with its ability to promote ȕ-oxidation in 
muscle allows PPARδ to regulate metabolic homeostasis 
and enhance insulin action by complementary effects 
in distinct tissues. The combined hepatic and peripheral 
actions of PPARδ suggest new therapeutic approaches to 
treat type II diabetes (8γ).
 It is now evident that PPARs, which are activated by 
various lipid molecules, function in distinct target tissues 
and coordinately regulate different metabolic pathways. 
PPARα and PPARδ potentiate fatty acid use in liver and 
muscle, respectively, whereas PPARȖ promotes lipid 
storage in adipocytes. In this dynamic system, lipids are 
shuttled between these tissues according to the needs of 
the body by lipoproteins. In this view, lipoproteins not 
only deliver energy substrates but also carry endogenous 
activators for
these receptors (68).
PPARs AND OBESITY
The cluster of medical sequelae, collectively referred to as 
the MetS, poses one of the most serious threats to public 
health that our society faces.Why does obesity carry with it 
a stereotyped collection of medical problems? That is, why 
is adipose tissue unable to store excess calories in a safe 
way? The answer to this question is not clear, but it may 
relect the reality that fat is not simply a storage depot, but 
rather a dynamic tissue that constantly communicates with 
other key tissues in the body, including liver,muscle and the 
appetite centers in the brain. In the past decade, tremendous 
advances in understanding this system of signals and 
sensors have been made, and the emergence of PPARs as 
key regulators of obesity and metabolism shedding light on 
how problems begin and how they may be therapeutically 
approached (41).
 The initial suggestion that PPARȖ stimulated 
adipogenesis was based on the abservation that 
overexpression of PPARȖ in cells was by itself suficient 
to induce adipocyte differentiation (54). Consistent with 
this, PPARȖ increases the expression of genes that promote 
fatty acid storage, whereas it represses genes that induces 
lipolysis in adipocytes (84).
 PPAR-Ȗ is a master regulator in the formation of fat 
cells and their ability to function normally in the adult 
(85). PPARȖ is induced during adipocyte differentiation, 
and forced expression of PPARȖ in nonadipogenic cells 
effectively converts them into mature adipocytes (54). In 
addition, PPARȖ knockout mice fail to develop adipose 
tissue (86,87,88). Consistent with these indings, humans 
with dominant-negative mutations in a single allele PPARG 
(the gene encoding PPARȖ) have partial lipodystrophy 
and insulin resistance (89,90,91). In vitro studies suggest 
that PPARȖ is the ultimate effector of adipogenesis in a 
transcriptional cascade that also involves members of the C/
EBP transcription factor family (9β,9γ). 
 Fat cells develop from a ibroblast-like preadipocyte 
to a mature, lipid-enriched adipocyte. The underlying 
transcriptional regulatory network that controls the 
maturation of adipocytes has been the focus of intense 
research and is reviewed elsewhere (94). 
 The highest levels of PPARȖ are expressed in 
adipose tissue (βγ,β4). In 1994, Spiegelman and colleagues 
discovered that expression and activation of PPARȖ was 
suficient to induce adipogenesis (54). The essential role of 
PPARȖ in adipogenesis has been clearly demonstrated in 
functional and genetic knockdown experiments (86,87).
 In addition to its importance in adipogenesis, PPARȖ 
plays an important role in regulating lipid metabolism in 
mature adipocytes. Much of what is known about this role 
of PPARȖ, and indeed many other aspects of its biology, 
followed the discovery that thiazolidinedione (TZD) 
antidiabetic drugs are highafinity agonist ligands for 
PPARȖ (6γ). TZDs appear to coordinately activate gene 
expression leading to an increase in net lipid partitioning into 
adipocytes. Target genes directly regulated by PPARȖthat 
are involved in this pathway include lipoprotein lipase
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(55), fatty-acid transport protein (95), and oxidized 
LDL receptor 1 (96), which all favor adipocyte uptake 
of circulating fatty acids; phosphoenolpyruvate 
carboxykinase (97,98), glycerol kinase (58), and the 
glycerol transporter aquaporin 7 (99), which promote 
recycling rather than export of intracellular fatty 
acids. Together, these pathways lead to the net ﬂux of 
fatty acids from the circulation and other tissues into 
adipocytes. Although increased fat storage would be 
expected to boost the size of adipocytes, TZD treatment 
actually leads to smaller adipocytes (100). This is 
partly due to increased adipocyte differentiation, 
leading to new smaller cells. In addition, TZDs induce 
the coactivator PPAR -coactivator 1a (PGC-1 ), which 
promotes mitochondrial biogenesis (101), leading to 
an increase in fatty-acid oxidation that further protects 
against adipocyte hypertrophy (102).
At a molecular level, how does activation of 
PPAR , a protein that is mainly present in adipose 
cells, lead to systemic insulin sensitization? Two 
plausible mechanisms should be considered. First, 
pharmacologic activation of PPAR  in adipose tissue 
improves its ability to store lipids, thereby reducing 
lipotoxicity in muscle and liver. This model involves 
activation of genes encoding molecules that promote 
a combination of lipid storage and lipogenesis, such 
as aP2 (fatty-acid binding protein), CD36 (receptor 
for lipoproteins), lipoprotein lipase (hydrolysis of 
lipoproteins), FATP-1 (fatty acid transporter), glycerol 
kinase, and SREBP-1 and SCD-1 (regulators of sterol 
and fatty acid synthesis, respectively). Activation 
of this metabolic pathway causes body-wide lipid 
repartitioning by increasing the TG content of adipose 
tissue and lowering free fatty acids and TG in the 
circulation, liver and muscle, thereby improving insulin 
sensitivity (58, 103). Second, PPAR -speciﬁc drugs alter 
the release of signaling molecules from fat, including 
leptin, TNF , resistin and adiponectin, which by virtue 
of serum transport have far-reaching metabolic effects 
in other tissues. For example, PPAR  agonists inhibit 
the expression of TNF  and resistin, which both 
promote insulin resistance (58,104,11105,106). On the 
other hand, PPAR  agonists stimulate the production 
of adiponectin, which promotes fatty acid oxidation 
and insulin sensitivity in muscle and liver. As a result, 
hepatic glucose production is reduced and muscle 
glucose use is increased (107,108,109). This pathway is 
mediated by adiponectin receptors and downstream 
AMP-activated protein kinase (110,111), making the 
intracellular AMP-activated kinase pathway another 
potential pharmacologic target for type 2 diabetes 
mellitus. Besides the aforementioned mechanisms, it 
is possible that PPAR  directly modulates the insulin 
signal transduction pathway in adipose tissue by 
increasing the expression of intracellular proteins such 
as c-Cbl-associated protein (CAP), which stimulates 
glucose transport (51).
There may be an appropriate level of PPAR /RXR 
activity for insulin sensitivity. This raise the  possibility 
that there may be a hitherto unrecognized U-shaped 
relationship between PPAR /RXR activity and insulin 
resistance within physiologically “normal” limits 
(Figure 3) (112).
Fig. 3. One possible model for the relatioship between PPAR /RXR activity and insulin sensitivity on the HF diet 
(Adapted from Yamauchi T et al, 2001).
12
The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.4-31 Print ISSN: 2085-3297, Online ISSN: 2355-9179
 Yamauchi et al have shown herein that PPARȖ/RXR 
promotes fat storage in the body by a combination of direct 
induction of molecules involved in TG accumulation and 
suppression of leptin gene expression as well as inactivation 
of PPARα−signaling pathways. In times of fasting, this 
PPARȖ/leptin/PPARα network maximizes energy storage, 
which is quite advantageous for survival. In times of feast, 
which are the norm in industrialized nations nowadays, 
however, this network causes excessive adiposity, insulin 
resistance, and obesity related diseases such as diabetes. 
Thus appropriate antagonism of PPARȖ/RXR, which 
simultaneously leads to appropriate agonism of leptin and 
PPARα, may be a logical approach to protection against 
obesity and related diseases such as type β diabetes (11β).
 PPARȖ, function as an important adipocyte 
determination factor. In contrast, TNFα inhibits 
adipogenesis, cause dedifferentiation of mature adipocytes, 
and reduces the expression of several adipocyte – speciic 
genes. Reduced PPARȖ gene expression is likely to 
represent an important component of the mechanism by 
which TNFα exerts its antiadipogenic effects (11γ).
 Insulin receptor substrate (IRS)-1 and IRS-β have 
dominant roles in the action of insulin (114), but other 
substrates of the insulin receptor kinase, such as Gab1, 
c-Cbl, SHβ-B and APS, are also of physiological relevance 
(115,116,117,118). Although the protein downstream 
of tyrosine kinases-1 (Dok1) is known to function 
as a multisite adapter molecule in insulin signaling 
(119,1β0,1β1), its role in energy homeostasis has remained 
unclear. Hosooka et al show that Dok1 regulates adiposity. 
Dok1 promotes adipocyte hypertrophy by counteracting 
the inhibitory effect of ERK on PPARȖ and may thus 
confer predisposition to
diet-induced obesity. (1ββ).
 The nuclear receptor corepressors NCoR and 
SMRT repress gene transcription by recruiting a histone 
deacetylase complex.Their roles in PPARȖ action 
have been controversial. Recent evidence, however, 
suggests that NCoR and SMRT repress PPARȖ-mediated 
transcriptional activity on speciic promoters in the 
adipocyte. In addition, by repressing PPARȖ action, these 
corepressors inhibit the ability of adipocyte differentiation 
to proceed (1βγ). 
 PPARδ initially received much less attention than 
the other PPARs because of its ubiquitous expression and 
the unavailability of selective ligands. However, genetic 
studies and recently developed synthetic PPARδ agonists 
have helped reveal its role as a powerful regulator of 
fatty acid catabolism and energy homeostasis (9,ββ). The 
PPARδ agonist GW501516 was shown to lower plasma 
TG levels in obese monkeys while raising high-density 
lipoprotein levels, prompting the initiation of clinical 
trials to assess its eficacy in hyperlipidemic patients (66). 
Studies in adipose tissue and muscle have begun to uncover 
the metabolic functions of PPARδ. Transgenic expression 
of an activated form of PPARδ in adipose tissue produces 
lean mice that are resistant to obesity, hyperlipidemia and 
tissue steatosis induced genetically or by a highfat diet. 
The activated receptor induces genes required for fatty 
acid catabolism and adaptive thermogenesis. Interestingly, 
the transcription of PPARȖ target genes for lipid storage 
and lipogenesis remain unchanged. In parallel, PPARδ-
deicient mice challenged with a high-fat diet show 
reduced energy uncoupling and are prone to obesity. 
Together, these data identify PPARδ as a key regulator of 
fat-burning, a role that opposes the fat-storing function of 
PPARȖ (64). Thus, despite their close evolutionary and 
structural kinship, PPAR-Ȗ and PPARδ regulate distinct 
genetic networks. The thermogenic function of PPARδ is 
markedly similar to that of the nuclear cofactor PGC-1α 
(1β4,1β5). Indeed, PPAR strongly associates with PGC-
1α both in cultured cells and in tissue, so it is possible 
that many metabolic effects of PGC-1α may be mediated 
through PPARδ(41).
 Upon agonist stimulation of PPARδ, KLF5 
was deSUMOylated, and became associated with 
transcriptional activation complexes containing both 
the liganded PPARδ and CREB binding protein (CBP). 
This activation complex increased the expression of 
Cpt1b, Ucpβ and Ucpγ. Thus, SUMOylation seems to 
be a molecular switch affecting function of KLF5 and 
the transcriptional regulatory programs governing lipid 
metabolism (1β6).
 Activation of PPARδ with the speciic agonist 
GW501516, however, coordinately upregulates 
expression of genes involved in fatty acid oxidation and 
energy uncoupling, which markedly diminishes weight 
gain while increasing Oβ consumption in mice fed a high-
fat diet (64, 1β7,1β8). Likewise, skeletal muscle–speciic 
overexpression of an activated form of PPARδ protects 
mice from diet-induced obesity. As a result, PPARδ is 
now considered to be an attractive target for treatment of 
metabolic syndrome (1β6). PPARδ as a nuclear receptor, 
represents a bonaide target. In particular, its ability to 
induce adaptive thermogenesis and protection against 
both dietary and genetic obesity (β4).
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PPARs AND CONTROL OF INFLAMMATORY 
RESPONSES
In addition to the regulation of lipid metabolism, PPARs 
and LXRs play roles in inﬂuencing inﬂammatory 
and immune responses. PPARs can be activated by 
eicosanoids, which are produced by metabolism 
of arachidonic acids and other long-chain PUFAs 
during inﬂammatory responses (36,48,49,59,129). For 
example, ligands for PPAR  are leukotriene LTB4 and 
8(S)-hydroxyeicosatetraenoic acid (HETE), whereas 
15deoxy-prostaglandin J2 (15d-PGJ2), 15- HETE, and 
13-hydroxyoctadecadienoic acid (HODE) act as ligands 
for PPAR . Interestingly, the expression of PPARs is 
differentially regulated by factors that control the 
development of immune responses. PPAR  expression 
is dramatically upregulated in macrophages and 
T cells during the inﬂammatory response and can 
be induced in vitro by interleukin (IL)-4 and other 
immunoregulatory molecules (130,131) In contrast, 
IFN  and lipopolysaccharide (LPS) repress the 
expression of PPAR  (132). PPAR  is highly expressed 
in elicited peritoneal macrophages, while low levels 
of PPAR  are present (133). The opposite pattern is 
observed in primary human monocytes (134). PPAR  
and PPAR  have been shown to inhibit the expression 
of proinﬂammatory genes, suggesting that they might 
inhibit inﬂammatory responses in vivo. Activation of 
PPAR  resulted in the induction of genes involved in 
fatty acid oxidation with the subsequent degradation 
of fatty acids and fatty acid derivatives like LTB4. 
In addition, the response to LTB4 and arachidonic 
acid was prolonged in mice lacking the PPAR  gene 
as compared with wild-type mice (135). However, 
some in vivo studies show proinﬂammatory effects 
for PPAR  ligands, such as an increase in the plasma 
levels of TNF  during endotoxemia (136) and in the 
production of monocyte chemoattractant protein 
(MCP-1) by endothelial cells (137). Thus, PPARs and 
LXRs negatively regulate transcriptional programs 
involved in the development of inﬂammatory 
responses (138).
PPAR  activators reduced cytokine-induced 
expression of VCAM-1 and ICAM-1 in human 
carotid artery endothelial cells in culture. Pasceri 
et al (139) reported that ﬁbrates reduced C-reactive 
protein (CRP)–induced expression of monocyte 
chemoattractant protein (MCP)-1 in human umbilical 
vein endothelial cells. With regard to clinical studies, 
Marchesi et al observed that 3-month therapy with 
fenoﬁbrate in hyperTGmic patients decreased VCAM-
1 and ICAM-1 levels in the fasting state. 
A molecular rationale for suppression of IL-1–
induced CRP transcription is provided by the fact that 
fenoﬁbrate upregulates I- B protein expression. This 
reduces nuclear translocation of p50–NF- B, resulting 
in decreased amounts of nuclear p50–NF- B and 
CCAAT/enhancer binding protein-  complexes, the 
major determinants of CRP transcription. These results 
provide strong evidence for a direct suppressive effect 
of fenoﬁbrate on CRP expression, independent of 
cholesterol lowering and atherogenesis (140,141). 
Endothelial dysfunction associated with the 
metabolic syndrome and other insulin-resistant states 
is characterized by impaired insulin-stimulated nitric 
oxide production from the endothelium and decreased 
blood ﬂow to skeletal muscle. Thus, improvement 
in insulin sensitivity leads to improved endothelial 
function (142).
Teissier et al extend our insight into the connections 
between PPARs, LDL metabolism, and oxidative stress 
(143). The oxidized form of LDL (ox-LDL) promotes 
inﬂammation in part via ox-LDL uptake by scavenger 
receptors and subsequent nuclear factor B activation. 
They ﬁnd that synthetic PPAR agonists induce the 
production of reactive oxygen species (ROS) in a 
PPAR –dependent manner by inducing NADPH 
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Moreover, these investigators offer the intriguing 
notion that ROS interact with LDL to activate PPAR  
and subsequently limit inﬂammation, as indicated by 
PPAR-dependent repression of inducible nitric oxide 
synthase (iNOS) gene transcription (145).
The PPAR –induced increase in ROS was 
attributable to the induction of NADPH oxidase, 
because (1) preincubation with the NADPH oxidase 
inhibitor diphenyleneiodinium prevented the increase 
in ROS production (2) PPAR  agonists increased 
O2 - production measured by superoxide dismutase–
inhibitable cytochrome c reduction  (3) PPAR  agonists 
induced mRNA levels of the NADPH oxidase subunits 
p47phox, p67phox, and gp91phox and membrane p47phox 
protein levels  and (4) induction of ROS production 
was abolished in p47phox-/- and gp91phox-/- macrophages. 
Finally, induction of NADPH  oxidase by  PPAR
agonists resulted in the formation of oxidized 
LDL metabolites that exert PPAR –independent 
proinﬂammatory and PPAR –dependent decrease 
of lipopolysaccharide-induced inducible nitric oxide 
synthase expression in macrophages. These data 
identify a novel mechanism of autogeneration of 
endogenous PPAR  ligands via stimulation of NADPH 
oxidase activity (143).
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Several reports (146,147,148) have indicated that 
PPAR  agonists reduce macrophage inﬂammatory 
responses, such as the elaboration of cytokines, nitric 
oxide, and matrix metalloproteinases (MMPs). In 
contrast, other reports have indicated that PPAR  
agonists stimulate the expression of proinﬂammatory 
receptors and cytokines (59,60,149,150,151). Finally, 
there are even reports that PPAR  agonists have no 
impact at all on macrophage inﬂammatory cytokine 
production (150,152).
PPAR  generally inhibits inﬂammatory response 
genes by negatively interfering with the NF- B, STAT, 
and AP-1 signaling pathways in a DNA-binding 
independent manner (153). Indeed, PPAR  modulates 
chemokine gene expression by inhibiting expression 
of MCP-1 and its receptor CCR2 in monocyte/
macrophages (154,155). PPAR  also plays a role in 
the regulation of CXC chemokine pathway. CXCR2 
upregulation by PPAR  leads to the acquisition of 
IL-8/Gro  responsiveness, as measured by enhanced 
reactive oxygen species (ROS) formation (156).
PPAR  expression in human ECs has been 
demonstrated by reverse transcription polymerase 
chain reaction (157) and more deﬁnitively using 
Western blotting and immunohistochemistry (158). 
Subsequent data suggested that PPAR  activation can 
inﬂuence target genes and processes that are of central 
relevance to endothelial biology. One such example is 
the role of chemokines (chemoattractant cytokines), 
signals for inﬂammatory cell recruitment (158).
Recently, Huang et al demonstrated that the 
PPAR  ligands, either 15-deoxy-∆ prostaglandin J2 
(15d-PGJ2) or ciglitazone, increased endothelial nitric 
oxide (•NO) release without altering endothelial nitric 
oxide synthase (eNOS) expression. However, the 
precise molecular mechanisms of PPAR -stimulated 
endothelial •NO release remain to be deﬁned. 
Superoxide anion radical (O2•-) combines with •NO 
to decrease •NO bioavailability. NADPH oxidase, 
which produces O2•-, and Cu/Zn-superoxide 
dismutase (Cu/Zn-SOD), which degrades O2•-, 
thereby contribute to regulation of endothelial cell 
•NO metabolism. These ﬁndings further elucidate 
the molecular mechanisms by which PPAR  ligands 
directly alter vascular endothelial function (159). 
CCAAT/enhancer-binding proteins (C/EBPs) 
upregulate transcription of various inﬂammatory 
cytokines and acute phase proteins, such as interleukin 
(IL)-1 , IL-6, TNF , and cyclooxygenase-2. Recent 
studies have demonstrated that PPAR  is present 
in atherosclerotic lesions, and negatively regulates 
expression of these genes. Interestingly, PPAR  gene 
promoter has tandem repeats of C/EBP-binding motif, 
and C/EBP-  plays a pivotal role in transactivation of 
PPAR  gene. Recent ﬁndings strongly suggest that C/
EBP-  is negatively autoregulated via transactivation 
of PPAR . This feedback mechanism probably 
downregulates transcription of inﬂammatory cytokines 
and acute phase proteins, and modulates inﬂammatory 
responses in the early process of atherosclerosis (160).
PPAR  controls the inﬂammatory status of the 
macrophage. Deletion of PPAR  from foam cells 
increased the availability of inﬂammatory suppressors, 
which in turn reduced atherosclerotic lesion area by 
more than 50%. Lee et al propose an unconventional 
ligand-dependent transcriptional pathway in which 
PPAR  controls an inﬂammatory switch through its 
association and disassociation with transcriptional 
repressors. PPAR  and its ligands may thus serve as 
therapeutic targets to attenuate inﬂammation and 
slow the progression of atherosclerosis (161).
PPAR , but not PPAR , is the major nuclear 
VLDL sensor in the macrophage, which is a crucial 
component of the atherosclerotic lesion. In addition 
to -oxidation and energy dissipation, activation of 
PPAR  by VLDL particles induces key genes involved 
in carnitine biosynthesis and lipid mobilization 
mediated by a recently identiﬁed TG lipase, transport 
secretion protein 2 (also named desnutrin, iPLA2 , and 
adipose TG lipase), resulting in increased fatty acid 
catabolism. Unexpectedly, deletion of PPAR  results 
in derepression of target gene expression, a phenotype 
similar to that of ligand activation, suggesting that 
unliganded PPAR  suppresses fatty acid utilization 
through active repression, which is reversed upon 
ligand binding. This unique transcriptional mechanism 
assures a tight control of the homeostasis of VLDL-
derived fatty acid and provides a therapeutic target for 
other lipid-related disorders, including dyslipidemia 
and diabetes, in addition to coronary artery disease 
(162).
Ligand activation of PPAR  in ECs has a potent 
antiinﬂammatory effect, probably via a binary 
mechanism involving the induction of antioxidative 
genes and the release of nuclear corepressors. PPAR  
agonists may have a potential for treating inﬂammatory 
diseases such as atherosclerosis and diabetes (163).
Administration of GW501516 to mice upregulated 
TGF- 1, whereas the expression of proinﬂammatory 
genes including MCP-1 was signiﬁcantly attenuated 
in the thoracic aorta. Taken together, these results 
demonstrate the presence of a novel TGF- 1
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mediated pathway in the antiinﬂammatory activities 
of PPAR  (164).
PPARs AND HYPERTENSION
The quest for better understanding for the 
pathophysiological basis of hypertension and 
atherosclerosis is ongoing. The complexity of 
hypertension and atherosclerosis and of the underlying 
mechanisms is becoming increasingly apparent (165).
Tordjman et al (166) explore the role of the 
candidate gene, PPAR ,  in the regulation of blood 
pressure and atherogenesis. PPAR  is believed 
to impart direct protection in the vessel wall by 
intervening at essentially every level of the atherogenic 
process: inﬂammation, monocyte recruitment and 
adhesion, cholesterol transport, plaque formation, 
and thrombosis, mostly through downregulation 
of NF- B and AP-1 (167,168,169).  In contrast to the 
plethora of data regarding the atherogenic process, 
the role of PPAR  in the regulation of vascular tone 
and blood pressure is still unclear. Several studies 
conducted in different rat models of hypertension 
yielded inconsistent results (170,171).
Evidence that PPAR  regulates the expression 
of the RAS starting with its rate-limiting step, renin. 
Based on the ﬁndings of the current study and on 
some published data, we suggest that, in the setting 
of an activated RAS and high endogenous levels of 
Ang II, PPAR  activation could be detrimental. In this 
context, PPAR  activation is likely to promote even 
higher levels of Ang II, increase oxidative stress, raise 
blood pressure, and ultimately hasten atherosclerosis. 
Further investigations aimed at delineating the 
relationships between the transcription factor PPAR  
and the components of the RAS and their respective 
molecular effectors are needed (166).
Evidence demonstrate that short-term cloﬁbrate 
treatment modulates vasomotor tone, producing effects 
that are consistent with antagonism of AT1-mediated 
but promotion of AT2-mediated renal and systemic 
hemodynamic effects of angiotensin II. These effects 
appear to involve nitric oxide production and are 
accompanied by concomitant changes in the expression 
of AT receptors – increased expression of AT2 receptors 
but diminished expression of AT1 receptors. PPAR  
ligands also protect against pathological damage 
especially resulting from angiotensin II hypertension 
(172).
Endothelin-1 (ET-1) is a vasoactive peptide that 
causes vasoconstriction and vasodilation by binding 
to ETA receptors on vascular smooth muscle cells 
and ETB receptors on endothelial cells, respectively 
(173,174,175).
The role of cytochrome P450 (CYP450) hydroxylase 
metabolites in the maintenance of arterial pressure is 
complex because of their contrasting hypertensive and 
antihypertensive properties (176). Cloﬁbrate, a PPAR  
agonist, has been shown to reduce arterial pressure in 
Dahl salt-sensitive rats on high salt diet by inducing 
the genes that code for CYP4504A (CYP4A) enzymes 
in the renal cortex (177,178). CYP4A is the enzyme 
responsible for the synthesis of 20-HETE. Interestingly, 
20-HETE has actions to reduce sodium transport and, 
like ETB receptor activation, has been implicated in 
salt-dependent hypertension (179,180,181,182,183). 
Therefore, chronic PPAR  agonist treatment reduces 
salt-dependent hypertension produced by ETB 
receptor blockade in male and female Sprague–
Dawley rats. This suggests a possible relationship 
between ETB receptor activation and the maintenance 
of CYP4A protein expression in the kidney of rats fed 
a high-salt diet (184).
Docosahexaenoic acid (DHA), PPAR  activator, 
reduces blood pressure in some hypertensive models by 
unclear mechanisms. PPAR  activator DHA attenuated 
the development of hypertension, corrected structural 
abnormalities, and improved endothelial dysfunction 
induced by Ang II. These effects are associated with 
decreased oxidative stress and inﬂammation in the 
vascular wall (180).
In the absence of dexamethasone, fenoﬁbrate 
lowered fasting TG and cholesterol but unexpectedly 
increased systolic blood pressure by ambulatory 
monitoring. These data suggest that PPAR  activation 
in humans does not correct insulin resistance induced 
by glucocorticoids and may adversely affect blood 
pressure (185).
The current study by Tordjman et al is of prime 
importance, because the investigators have successfully 
focused our attention on a controversy that involves 
PPAR . This central molecule which action had been 
considered until now beneﬁcial and a prime therapeutic 
target, may in fact turn out to be a candidate gene for 
hypertension and for atherosclerosis and, thus, a foe 
to human health. More in-depth research is required 
to establish if, when, and how PPAR  might indeed 
be involved in the generation of high blood pressure 
and atherosclerosis in humans, issues that remain, at 
present, unresolved (165).
PPAR  is an attractive molecule given its role 
as a fatty acid sensor and the increased incidence of 
hypertension in obese patients. It remains possible that
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PPAR  may represent a link among obesity, 
metabolic dysfunction, and activity of either the 
circulating or tissue renin-angiotensin system in 
hypertension. There is no doubt that the mechanisms 
regulating the renin-angiotensin system by PPAR  
will prove to be quite complex given the positive 
stimulation on renin transcription reported in this 
issue, along with the negative impact on the AT1 
receptor reported previously. That TZDs are generally 
thought to modestly lower blood pressure suggests 
that a delicate balance must exist between the effects of 
PPAR  on the renin-angiotensin system (renin versus 
AT1 receptor) and other vasoconstrictors, such as ET-1 
(186).
Among the transcription factor binding sites in 
the enhancer is the hormone response element (HRE). 
Several members of the nuclear hormone receptor 
superfamily, including retinoic acid receptor and RXR, 
have been shown to bind to the HRE and to regulate 
renin gene expression (187). In addition, vitamin D 
has been reported to negatively modulate renin gene 
expression through a vitamin D receptor– dependent 
mechanism, which may involve the HRE (187,188). 
Because the HRE is homologous to a PPRE, and 
PPAR , retinoic acid receptor- , RXR , and vitamin 
D receptor are all members of the same subfamily of 
ligand-activated transcription factors, it should not 
be surprising that PPAR  may have to be included 
among those transcription factors thought to regulate 
renin expression.
PPAR  activation by TZDs causes a down-
regulation of AT1 receptor gene expression via a 
PPAR -dependent mechanism in vascular smooth 
muscle cells. Therefore, PPAR  may play a role in the 
regulation of Ang II action (189).
PPARs AND THE METABOLIC SYNDROME
Metabolic syndrome (MetS) is a cluster of metabolic 
abnormalities, which is characterized by abdominal 
obesity, insulin resistance, dyslipidemia, elevated blood 
pressure, and a proinﬂammatory and prothrombotic 
milieu (200,201).
MetS appears to affect a signiﬁcant proportion 
of the population. While up to 80% of the almost 
200 million adults worldwide with diabetes will die 
of CVD, people with MetS are also at increased risk, 
being twice as likely to die from and three times as 
likely to have a heart attack or stroke compared to 
people without the syndrome (192). Subjects with 
MetS have a ﬁve – fold greater risk of developing T2D 
if not already present (193).
Whether or not it is accepted that MetS is a speciﬁc 
disease entity or just a constellation of symptoms, the 
prevalence of this condition is increasing worldwide 
and patients need to tackle these risk factor through 
either lifestyle or pharmacological approaches, in 
order to reduce the odds of developing diabetes and 
cardiovascular disease (CVD) (194).
PPARs are intimately involved in nutrient 
sensing and the regulation of carbohydrate and lipid 
metabolism. PPAR  and PPAR  appear primarily to 
stimulate oxidative lipid metabolism, while PPAR  
is principally involved in the cellular assimilation of 
lipids via anabolic pathways. These may nevertheless 
have much greater signiﬁcance for the public health 
burden in the abnormal lipid and carbohydrate 
metabolism of the MetS (195).
One of the hallmarks of MetS is depressed levels 
of HDLC, which occurs in 37% of patients with MetS 
(194). Whereas HDLC is not the primary target of lipid-
modulating therapy, it is recognized as an important 
secondary target of therapy, and, thus, treatments that 
raise HDLC may be important in reducing CVD risk 
(197).
The identiﬁcation of PPARs as molecular targets 
for drugs to treat hypertriglyceridemia and type 2 
diabetes mellitus has fueled interest in their biology 
and potential as targets to treat the metabolic 
syndrome (198). In keeping with their roles as lipid 
sensors, ligand-activated PPARs turn on feed-forward 
metabolic cascades to regulate lipid homeostasis via 
the transcription of genes involved in lipid metabolism, 
storage, and transport. Additionally, PPARs may 
suppress inﬂammation through mechanisms 
involving the release of antiinﬂammatory factors or the 
stabilization of repressive complexes at inﬂammatory 
gene promoters (161,199).
The pathophysiology underlying the MetS is 
incompletely understood, but insulin resistance 
appears to be an important component (199,200). 
Insulin resistance is marked by hyperinsulinemia, 
enhanced hepatic gluconeogenesis, and impaired 
insulin-stimulated glucose uptake into skeletal muscle 
and fat. Elevated levels of circulating FFAs, associated 
with obesity and insulin resistance, increase fat 
accumulation in insulin target tissues and contribute to 
defective insulin action. Obese adipose tissue–derived 
inﬂammation and altered adipokine secretion may also 
inhibit insulin signals and affect systemic metabolism 
(201). The resulting hyperglycemia, dyslipidemia, 
hypertension, and inﬂammation of the MetS cause 
endothelial dysfunction and hasten atherogenesis 
(198).
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Hypertriglyceridemia and abdominal obesity are 
key components of the MetS. They may result from 
an inability of adipose tissue to sequester fatty acids 
appropriately for storage (202). Instead, fatty acids 
are deposited as ectopic fat in skeletal muscle (203), 
liver (204), and other organs (205). It is thought that 
such fat accumulation is linked to impaired metabolic 
function of the tissue (206,207). Obesity-related insulin 
resistance involves the release of mediators, such as 
FFAs, TNF , or resistin from adipocytes and decreased 
production of adiponectin, all of which impair insulin 
action in skeletal muscle (207).
Adipose tissue as an endocrine organ also releases 
proinﬂammatory mediators that promote vascular 
damage and atherosclerosis. TNF  inhibits insulin 
signaling contributing to insulin resistance and activates 
multiple mechanisms of inﬂammation via NF- B (208). 
Leptin can alter insulin action and has recently been 
recognized to be an important mediator of obesity-
related hypertension (209). Angiotensinogen, the 
precursor of angiotenin II, a key mediator of vascular 
injury, can be produced and secreted by adipose tissue 
(210). Plasminogen activator inhibitor 1 (PAI-1) is 
typically increased in the obesity/insulin-resistance 
state and plays an important role in atherothrombosis 
(211,212). In contrast, excessive visceral adipose tissue 
has been shown to be associated with decreased 
adiponectin levels (111), an important hormone that 
exerts antidiabetic (109,110) and antiatherogenic 
functions (213,214). Adiponectin activates AMP-
activated protein kinase, which promotes skeletal 
muscle glucose uptake and suppresses hepatic glucose 
production (110). Importantly, adiponectin also inhibits 
NF- B activation, thus, attenuating inﬂammation (215). 
Visfatin, a growth factor with insulin mimetic action, 
was recently cloned from fat (216). Unlike adiponectin, 
plasma levels of visfatin increase in parallel with 
visceral fat in both mice and humans (216), so the 
role of visfatin in insulin resistance needs additional 
investigation. Taken together, these observations 
suggest that the adipocyte is an integral coordinator 
of the relationship among obesity, diabetes, and CVD 
(207).
Interestingly, it is possible that the intra – 
myocellular lipid (IMCL) impact on insulin sensitivity 
might be modulated by the oxidative disposal of long-
chain fatty acyl-CoAs, depending on the efﬁciency 
of the regulation of its ﬂux and metabolism within 
the mitochondrion. These latest ﬁndings represent a 
fascinating and promising novel understanding linking 
small abnormalities of tissue energy metabolism to a 
steady tendency toward both weight gain and ectopic 
fat accumulation – particularly in skeletal muscle – as 
a common denominator inducing both obesity and 
insulin resistance (203).
The PPAR  agonist GW501516 attenuated 
multiple metabolic abnormalities normally associated 
with the MetS in humans, and this was probably 
due to an increase in skeletal muscle fatty acid 
oxidation. Presently, the individual components of the 
MetS are treated separately; i.e., statins are used for 
elevated cholesterol, ﬁbrates are used to reduce TG, 
and metformin and thiazolidinediones are used for 
hyperglycemia. The wide range of beneﬁcial effects 
suggested by the response to GW501516 calls for a 
larger study in patients to evaluate the clinical efﬁcacy 
of PPAR  agonists for the treatment of hyperlipidemia, 
liver fat accumulation, obesity, and insulin resistance 
(217). Thus, PPAR  is pivotal to control the program 
for fatty acid oxidation in the skeletal muscle, thereby 
ameliorating obesity and insulin resistance through its 
activation in obese animals (128).
Accelerated atherosclerosis is a major cause of 
morbidity and death in insulin-resistant states such as 
obesity and the MetS, macrophages from obese (ob/ob) 
mice have increased binding and uptake of oxidized 
LDL, in part due to a posttranscriptional increase in 
CD36 protein. Macrophages from ob/ob mice are also 
insulin resistant, as shown by reduced expression and 
signaling of insulin receptors. Defective macrophage 
insulin signaling predisposes to foam cell formation 
and atherosclerosis in insulin-resistant states and 
that this is reversed in vivo by treatment with PPAR  
activators (218).
Obesity and insulin resistance, the cardinal 
features of MetS, are closely associated with a state of 
low-grade inﬂammation (219,220). In adipose tissue 
chronic overnutrition leads to macrophage inﬁltration, 
resulting in local inﬂammation that potentiates insulin 
resistance (220,222).
PPAR  is required for maturation of alternatively 
activated macrophages. Disruption of PPAR sw 
in myeloid cells impairs alternative macrophage 
activation, and predisposes these animals to 
development of diet-induced obesity, insulin 
resistance, and glucose intolerance. Furthermore, gene 
expression proﬁling revealed that down regulation 
of oxidative phosphorylation gene expression in 
skeletal muscle and liver leads to decreased insulin 
sensitivity in these tissues. These suggest that resident 
alternatively activated macrophages have a beneﬁcial 
role in regulating nutrient homeostasis and suggest 
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that macrophage polarization towards the alternative 
state might be a useful strategy for treating T2D (223).
PPARs AS THERAPEUTICS TARGETS FOR MetS
Because these nuclear receptors are activated by 
extracellular signals and control multiple gene targets, 
PPARs can be seen as nodes that control multiple inputs 
and outputs involved in energy balance, providing 
insight into how metabolism and the vasculature may 
be integrated. The ongoing clinical use of ﬁbrates, 
which activate PPAR , and thiazolidinediones, which 
activate PPAR , establishes these receptors as viable 
drug targets, whereas considerable in vitro animal 
model and human surrogate marker studies suggest 
that PPAR activation may limit inﬂammation and 
atherosclerosis. Together, these various observations 
have stimulated intense interest in PPARs as therapeutic 
targets and led to large-scale cardiovascular end-point 
trials with PPAR agonists (224).
The current clinical approach to MetS is to focus 
on appropriate management of accompanying risk 
factors. While priority should be given to management 
of underlying risk factors with therapeutic lifestyle 
changes, associated major risk factors should be 
treated according to evidence – based medicine goals 
and principles, and appropriate clinical attention 
should be given to the presence of emerging risk 
factors. Clearly, there are multiple targets for therapy 
to reduce the high risk of the MetS. While no single 
treatment for the MetS as a whole yet exist, it is well 
established that lifestyle changes, for example, changes 
in diet and increased physical exercise, form the ﬁrst 
– line strategy of intervention (194).
In MetS, a condition of impaired fatty acid 
metabolism in adipose tissue generally results in the 
increased release of free fatty acids into the circulation. 
This in turn leads to multiple abnormalities in the 
circulating lipoprotein proﬁle including low HDL, high 
TG, and VLDL remnants, with average LDL. The triad 
of elevated TG, reduced HDL and small dense LDL, 
along with concomitant increased in TG – rich remnant 
particles, comprises the atherogenic dyslipidemia 
of MetS. MetS, with or without progression to T2D, 
is therefore a major atherogenic factor. CHD risk 
reduction in MetS requires not only aggressive LDL 
– C lowering but also management of each aspect of 
dyslipidemia, including lowering TG levels, increasing 
HDL – C levels, and increasing the size of the average 
LDL – C particle. Based on available evidence, LDL 
– C is the primary target of therapy in MetS (223). In 
patients with atherogenic dyslipidemia with elevated 
TG, non – HDL – C represents a secondary target of 
treatment after the LDL – C goal is achieved. The 
tertiary goal in these patients is to raise HDL – C when 
it is reduced after attaining goals for LDL – C and non 
– HDL – C (194).
PPAR activation can improve metabolic parameters 
like glucose and lipid levels but also alter directly 
vascular responses by regulating target genes including 
those encoding adhesion molecules, The ATP – binding 
cassette transporter 1 (ABCA 1), lipoprotein lipase, 
cytokines and chemokines (226). PPAR activation has 
many anti – atherosclerotic effects with disctinct and 
overlapping targets. For instance, lipoprotein lipase 
acts on circulating lipoproteins to activate PPAR  and 
intiates PPAR  – dependent positrive feedback loop 
for TG – rich lipoprotein catabolism (44). Exogenist 
PPAR  agonist such as fenoﬁbrate reduce TNF  
– induced activation of NF-  (227), a transcription 
factor integrating inﬂammation and atherosclerosis. 
There have been indications that PPAR  is involved 
in the pathogenesis of insulin resistance. In this 
regard, PPAR  knockout mice are protected from diet 
– induced insulin resistance probably because of of 
inhibition of PPAR  - dependent  fatty acid oxidation 
(227). By contrast, genetic defects in PPAR  can 
recapitulate all the salient features of MetS in humans 
(96). Therefore, PPARs are likely to be involved in the 
development of MetS and, accordingly, can serve as 
potential therapeutic targets for the prevention and 
treatment of MetS (228).
Activation of PPAR  by ﬁbrates stimulates the 
oxidation of free fatty acids in the liver (229), diverting 
them away from TG synthesis and thus reducing 
the hepatic synthesis of TG-rich lipoproteins (230). 
The activation of PPAR  also induces expression 
of the gene for lipoprotein lipase (LPL), the enzyme 
responsible for hydrolyzing TG and phospholipids in 
TG-rich lipoproteins in plasma (231). Thus, activators 
of PPAR  lower the concentration of plasma TG by 
reducing its rate of synthesis and increasing its rate of 
hydrolysis. An additional effect of activating PPAR  
is the inhibition of synthesis of apolipoprotein (apo) 
C-III (232). Because apoC-III delays the catabolism of 
TG-rich lipoproteins, its inhibition provides a further 
mechanism by which PPAR -activators such as 
ﬁbrates lower the concentration of plasma TG. Fibrates 
also impact on the concentration of HDLC in humans, 
although the precise mechanisms are not known. 
Fibrates increase expression of the genes for both apo 
A-I and apo A-II, the 2 main apolipoproteins of HDL 
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Fig. 4. Effects of ﬁbrates with the potential to protect against cardiovascular disease (Adapted from Barter PJ, 2008).
(233,234), although the magnitude of the increases 
in the plasma concentrations of these proteins tends 
to be small. Generally, the increase in plasma apoA-
II is greater than that of apoA-I (234,235,236). This 
results in an increase in the concentration of HDL 
particles containing both apoA-I and apoA-II but a 
decrease in those containing apoA-I without apoA-II 
(236). Other potential mechanisms by which ﬁbrates 
increase the level of HDLC include an enhancement 
of cell cholesterol efﬂux secondary to an induction of 
cell ABCA1 expression (237), although others have not 
been able to conﬁrm this (238). Fenoﬁbrate has been 
reported to decrease SR-B1 in the liver (239), an action 
that would contribute to an elevation of HDLC but 
which may not necessarily translate into a reduction 
in atherosclerosis. Fibrates also increase LDL particle 
size (142,240) and decrease the concentration of TG-
rich lipoprotein remnants. These latter effects are 
potentially antiatherogenic and appear to be mediated 
equally well by all ﬁbrates. Post hoc analyses of 
several of the ﬁbrate studies have shown that people 
with features of the MetS, particularly overweight 
people with high plasma TG levels and low levels of 
HDL cholesterol, derive a disproportionately large 
reduction in cardiovascular events when treated with 
these agents. Thus, there is a strong case for the use of a 
ﬁbrate to reduce the cardiovascular risk in overweight 
people with high TG and low HDLC (241).
PPAR  is essential for normal adipocyte 
differentiation and proliferation as well as fatty acid 
uptake and storage. Thiazolidinediones increase the 
number of small adipocytes and the subcutaneous 
adipose-tissue mass in studies in animal models 
(100,242,243). These observations, plus the high level 
of PPAR  expression in adipose tissue, have led to the 
hypothesis that thiazolidinediones exert their insulin-
sensitizing actions either directly (the “fatty acid 
steal” hypothesis) or indirectly, by means of altered 
adipokine release, modulating insulin sensitivity 
outside adipose tissue. According to the “fatty acid 
steal” hypothesis, thiazolidinediones promote fatty 
acid uptake and storage in adipose tissue. In this 
way, they increase adipose-tissue mass and spare 
other insulin-sensitive tissues such as skeletal muscle 
and the liver, and possibly pancreatic beta cells, from 
the harmful metabolic effects of high concentrations 
of free fatty acids. Thiazolidinediones thus keep fat 
where it belongs.
Various adipokines, such as adiponectin 
(244,245), TNF  (246), resistin (247), and 11 -
hydroxysteroid dehydrogenase 1, the enzyme that 
produces cortisol locally in adipose tissue (242,248), 
are among the genes that are regulated by PPAR  
agonists in rodents. Of these, adiponectin increases 
insulin sensitivity, and TNF , resistin, and 11 -
hydroxysteroid dehydrogenase 1 (249) induce insulin 
resistance in rodents. Adiponectin, an adipocytokine 
produced exclusively by adipose tissue, has both 
insulin-sensitizing and antiatherogenic properties in 
mice (244,245). PPAR  agonists increase adiponectin 
expression in vitro in adipose tissue (250).
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In the liver and in adipose tissue, 11 - hydroxysteroid 
dehydrogenase 1 catalyzes the interconversion of 
cortisone to cortisol (251). A full-blown MetS characterized 
by obesity and the accumulation of visceral fat, as well 
as increased concentrations of cortisol in the portal 
vein but not of systemic cortisol, develops in mice that 
overexepress 11 -hydroxysteroid dehydrogenase 1 in 
adipose tissue (249). Thiazolidinediones down-regulate 
11 -hydroxysteroid dehydrogenase 1 expression in 
adipose tissue (250) and might thereby alleviate features 
of the MetS.
Study of Samaha et al (252) found overall favorable 
effects of rosiglitazone on adipokines, including 
a signiﬁcant increase in adiponectin levels. This 
increase in adiponectin may be attributable to a direct 
effect of rosiglitazone on adipocytes, and possibly 
macrophages (253). Adiponectin has been shown to 
play a role in modulating insulin sensitivity and to be 
increased by rosiglitazone in patients with diabetes 
(254). Furthermore, increasing quintiles of adiponectin 
levels have been associated with decreased risk of 
myocardial infarction (255). 
Study also demonstrates that rosiglitazone lowers 
resistin levels in patients with MetS, as recently 
demonstrated in one small study of 14 patients 
with T2D (256). In humans, however, resistin is 
predominantly produced by macrophages in response 
to inﬂammatory stimuli and is almost undetectable 
in adipose tissue. Rosiglitazone may thus have a 
direct effect on resistin expression, such as through 
macrophage PPAR  activation. We have recently 
shown that resistin levels independently correlate 
with degree of coronary artery calciﬁcation (257). 
Rosiglitazone also signiﬁcantly reduced levels 
of CRP, IL-6, and sTNF  R2. (258). Similar responses 
for CRP and IL-6 were previously found in patients 
with diabetes (259). A signiﬁcant correlation between 
the rosiglitazone-induced changes in resistin and 
changes in the inﬂammatory markers IL-6 and sTNF  
R2. These ﬁndings are consistent with our previous 
ﬁndings of a signiﬁcant correlation between baseline 
levels of resistin and sTNF  R2. (258). Rosiglitazone 
has been shown to lower CRP in nondiabetic patients 
with coronary artery disease (260) and in nonobese 
Taiwanese patients with MetS (261).
These ﬁndings suggest that rosiglitazone, 
presumably through its PPAR  agonist properties, has 
direct effects on inﬂammatory markers and adipokines 
in the absence of favorable lipid effects. These ﬁndings 
may help explain the mechanism underlying the 
possible antiatherosclerotic effects of rosiglitazone 
(252).
Current pharmacologic approaches are 
unsatisfactory in improving such consequences 
of insulin resistance as hyperglycemia, diabetic 
dyslipidemia, abnormal coagulation and ﬁbrinolysis, 
and hypertension, each of which may require the use 
of at least one medication. Thus, the development 
of drugs targeted to reverse insulin resistance is 
important. The insulin-sensitizing thiazolidinediones, 
which are selective ligands of the PPAR , are the ﬁrst 
drugs to address the basic problem of insulin resistance 
in patients with MetS and T2D (262).
It is noteworthy that TZDs show intracellular 
antioxidant activity. This property may reﬂect 
‘preventative’ action since these agents do not show 
direct antioxidant scavenging activity on free radicals, 
but block several mechanisms that in hyperglycaemic 
or hyperlipidaemic conditions lead to the generation of 
oxidative stress. It has been observed that PPAR ligands 
inhibit the expression of inducible NO synthase (iNOS) 
cells and in cerebellar granule cells (133).
The antagonising activity of NF- B is also of 
relevance in this setting, since it is through this 
mechanism that rosiglitazone and pioglitazone can 
reduce iNOS over-expression, and the related over-
production of nitrotyrosine during experimental 
myocardial infarction (263).
Such effects may explain the ability of pioglitazone 
to reduce oxidative stress in type 2 diabetic patients 
after a meal (263). It is not surprising therefore that 
pioglitazone can improve endothelial dysfunction in 
cardiovascular disease patients, both with and without 
T2D and MetS (265,266).
PPAR  activation by the TZDs results in an 
array of effects on traditional and non-traditional 
cardiovascular risk factors that are independent of their 
effects on glycaemic control. These include reduction 
of IMT progression and circulating platelet activity, 
attenuation of PAI-1 expression, inhibition of glycation, 
increase in plasma adiponectin and reduction of CRP, 
IL-6 and MMP-9 levels. There is evidence that many 
of the anti-atherogenic and anti-inﬂammatory effects 
of the TZDs may be attributable to the glitazone class, 
although no head-to-head studies have been carried 
out to establish comparative efﬁcacy (267).
There continues to be uncertainty about the 
risk of ischemic heart disease in patients with T2D 
associated with the use of rosiglitazone (268). There 
was no evidence of any increase in death from either 
cardiovascular causes or all causes. Rosiglitazone was 
associated with an increased risk of heart failure. 
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Fig. 5. TZDs affect oxidative stress and inﬂammation at multiple levels (adapted from Ceriello A, 2008).
The data were insufﬁcient to determine whether 
the drug was associated with an increase in the risk of 
myocardial infarction (269). Caution should be used in 
patients with underlying heart disease using nitrates, 
and when added to ongoing insulin-based therapy 
(268).
A hallmark of the MetS is dyslipidemia, marked 
by elevated TG and low levels of HDLC. HDL is a 
driving force in the process of reverse cholesterol 
transport, reclaiming excess peripheral tissue 
cholesterol to the liver for excretion. Accordingly, low 
levels of HDL are associated with an increased risk 
of coronary artery disease and cardiovascular death 
in afﬂicted patients, while overexpression of apoA-I, 
the major apolipoprotein composing HDL particles, 
retards atherogenesis in animal models (270,271,272). 
Despite clear therapeutic need, currently marketed 
cholesterol-modifying drugs raise serum HDL levels 
only modestly. 
High-afﬁnity PPAR  ligands have revealed an 
important role for PPAR  in lipoprotein metabolism. 
Treatment of insulin-resistant obese rhesus monkeys 
with the PPAR -selective agonist GW501516 resulted 
in a dramatic 79% increase in HDLC, a 56% decrease 
in TG, and a 29% decrease in LDLC (66). The profound 
increase in HDLC levels correlated with an increase 
in number, not size, of HDL particles and was 
accompanied by increased serum levels of the HDL-
associated apolipoproteins apoA-I, apoA-II, and apoC-
III. In addition, fasting insulin levels declined by up to 
48% in the PPAR  drug–treated animals (66). Obese and 
nonobese mice similarly develop an increase of up to 
50% in HDLC levels when treated with PPAR  agonists 
(273,274). The mechanism by which PPAR  activation 
raises HDLC levels remains to be elucidated, but 
studies to date indicate that expression of the reverse 
cholesterol transporter ABCA1 is enhanced in some 
tissues upon exposure to PPAR  agonists, including 
human and mouse macrophages as well as human 
intestinal cells and ﬁbroblasts (66,273). Additional 
work suggests that PPAR  activation reduces 
intestinal cholesterol absorption via downregulation 
of the Niemann-Pick C1–like 1 gene (NPC1L1) (273). 
NPC1L1 is a key mediator of intestinal cholesterol 
absorption and a putative target for the clinically used 
cholesterol absorption inhibitor ezetimibe. In light of 
these ﬁndings, PPAR  drugs are now in clinical trial 
for the treatment of human dyslipidemia.
Once viewed as a bland storage depot, adipose 
tissue has emerged as a dynamic endocrine organ 
(201). Adiposity correlates with insulin resistance 
and is believed by some to be of primacy in the MetS 
(275). Even mild weight loss may improve serum 
lipid proﬁles, glycemic control, and hypertension, yet 
currently available weight-loss drugs are of limited 
effectiveness (276,277). Genetic models and ligand 
treatment studies have uncovered powerful regulatory 
functions for PPAR  in adipose tissue metabolism and 
weight control. Transcriptional analysis of brown fat in 
fat-speciﬁc VP16-PPAR mice revealed upregulation of 
genes involved in TG hydrolysis (hormone-sensitive 
lipase), fatty acid oxidation (long-chain acyl-CoA 
synthetase, very-long-chain acyl-CoA synthetase, 
acyl-CoA oxidase), and uncoupling of oxidative 
phosphorylation (UCP1 and UCP3). UCP1 expression 
was likewise elevated in white adipose tissue. 
Conversely, PPAR -null mice are more susceptible to 
weight gain and have blunted expression of brown 
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fat UCP1 on a high-fat diet. These genetic models 
collectively suggest that activation of PPAR  protects 
against obesity (164).
Administration of the synthetic PPAR  agonist 
GW501516 to genetically obese (db/db) mice reduced 
intracellular TG accumulation in the brown fat 
and liver, analogous to the effects of VP16-PPAR . 
Moreover, PPAR  agonists enhanced -oxidation in 
3T3-L1 preadipocytes by 50% (164). Most importantly, 
PPAR  ligands retard weight gain in models of high-fat 
diet–induced obesity (128,164). These results suggest 
that PPAR  synthetic drugs may be therapeutic as 
antiobesity agents. 
PPAR  has emerged as a powerful metabolic 
regulator in diverse tissues including fat, skeletal 
muscle, and the heart. Its transcriptional program 
enhances fatty acid catabolism and energy uncoupling, 
resulting in decreased TG stores, improved endurance 
performance, and enhanced cardiac contractility, 
respectively. PPAR  receptor activation mitigates 
macrophage inﬂammatory responses and modulates 
lipoprotein metabolism to lower TG and robustly 
raise HDLCl. Additionally, recent studies reveal that 
PPAR  activation in the liver suppresses hepatic 
glucose output, contributing to improved glucose 
homeostasis (278). These aggregate effects suggest 
that high-afﬁnity PPAR  synthetic drugs may 
uniquely target multiple components of the MetS, 
including obesity, insulin resistance, hyperglycemia, 
dyslipidemia, and atherosclerosis, or other diseases 
such as cardiomyopathy (Figure 6) (198).
Research programs to develop agonists that 
combine the therapeutic effects of both PPAR  and 
Fig. 6. Therapeutic targets of PPAR  in the MetS (Adapted from Barish GD, 2006).
PPAR  selective agonists, creating the expectation of 
synergy in the treatment of T2D and the MetS, have 
therefore been undertaken. Among these dual PPAR /
 agonists, compounds belonging to the glitazar class 
have been advanced to clinical development (Phases 
II and III). These trials clearly demonstrate superior 
efﬁcacy of these compounds in correcting abnormalities 
associated with T2D and the MS, improving both lipid 
and glucose homeostasis to a greater extent than did 
selective PPAR agonists. However, safety remains 
a critical issue for glitazars, as the development of 
several promising candidates was halted because of 
adverse toxicity proﬁles (279).
The discovery and preliminary biological and 
pharmacokinetic properties of muraglitazar (BMS-
298585), a novel oxybenzylglycine dual ( / ) PPAR 
activator, have been recently described. Muraglitazar 
binds with high afﬁnity to both human PPAR  and 
PPAR  ligand binding domain protein (IC50 for 
binding = 0.19 and 0.25 µmol/l, respectively) and 
potently transactivates full-length human PPAR - or 
PPAR -mediated reporter gene activity (EC50 for 
transactivation = 0.11 and 0.32 µmol/l, respectively). 
Harrity et al (280) assessed the effects of muraglitazar 
treatment on diabetes and other metabolic abnormalities 
in genetically obese, diabetic, and hyperlipidemic db/
db mice. 
Tesaglitazar, a Novel Dual PPAR /  agonist, dose 
– dependently improves the metabolic abnormalities 
associated with insulin resistance in a non – diabetic 
population (281). Macelignan, a natural compound 
isolated from Myristica fragrans, enhanced insulin 
sensitivity and improved lipid metabolic disorders 
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by activating PPAR /  and attenuating ER stress, 
suggesting that it has potential as an antidiabetes 
agent for the treatment of T2D and MetS (282).
However, current safety standards with 
compounds for T2D and the MetS are high, and few 
adverse effects are currently tolerated. We believe that 
the best solution would be to screen for compounds 
that combine an intermediate PPAR  afﬁnity with 
selective PPAR  - modulating activity (279).
Conclusion
The MetS is diagnosed by a cluster of clinical parameters 
including central obesity, atherogenic dyslipidemia, 
raised blood pressure and hyperglycemia. Visceral 
obesity, hepatic steatosis and insulin resistance have 
been proposed as unifying mechanisms, yielding 
a prothrombotic and proinﬂammatory state. 
Consequently, patients with MetS are at increased risk 
of CAD and T2D.
The discovery of the crucial role of peroxisome 
proliferator–activated receptors (PPARs) as regulators 
of lipid and glucose metabolism has raised interest in 
the development of synthetic ligands as potential tools 
for therapeutic intervention in T2D and the MetS.
References:
1. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant 
C. Deﬁnition of metabolic syndrome: report of the National 
Heart, Lung, and Blood Institute/American Heart Association 
conference on scientiﬁc issues related to deﬁnition. 
Circulation 2004; 109: 433 – 438.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo 
E, Tuomilehto J, et al. The metabolic syndrome and total 
and cardiovascular disease mortality in middleaged men. 
JAMA 2002; 288: 2709 – 2216.
3. Shulman AI, Mangelsdorf DJ. Retinoid X Receptor Heterodimers 
in the Metabolic Syndrome.  N  Engl J Med 2005; 353: 604 
– 615.
4. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inﬂamed 
Adipose Tissue. A Culprit Underlying the Metabolic 
Syndrome and Atherosclerosis. Arterioscler Thromb Vasc 
Biol 2007; 27: 2276 – 2283.
5. Sonnenberg G, Krakower R, Kissebah AH. A Novel Pathway to 
the Manifestations of Metabolic Syndrome. Obes Res 2004; 
12: 180 – 186.
6. Taskinen MR. Is Metabolic Syndrome the Main Threat to Human 
health in te Twenty – First Century? Arterioscler Thromb 
Vasc Biol 2007; 27: 2275.
7. Morales LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-
activated receptors and inﬂammation. Pharmacol Ther 
2006; 110: 371 – 385.
8. Bishop-Bailey D, Wray J. Peroxisome proliferator-activated 
receptors: a critical review on endogenous pathways for 
ligand generation. Prostaglandins Other Lipid Mediat 2003; 
71: 1 – 22.
9. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, et al. 
Effects of peroxisome proliferator-activated receptor delta 
on placentation, adiposity, and colorectal cancer. Proc Natl 
Acad Sci U S A 2002; 99: 303 – 308.
10. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, 
Rieusset J, et al. Impaired skin wound healing in peroxisome 
proliferator-activated receptor (PPAR)alpha and PPARbeta 
mutant mice. J Cell Biol 2001; 154: 799 – 814.
11. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, 
Gonzalez FJ, et al. International Union of Pharmacology. 
LXI. Peroxisome proliferator-activated receptors. Pharmacol 
Rev 2006; 58:726 –741.
12. Bishop –Bailey D. Peroxisome Proliferator – Activated Receptor 
/  Goes Vascular. Circ Res 2008; 102: 146 – 147.
13. Mudaliar S, Henry RR. PPAR Agonist in Health and Disease: 
a Pathophysiologic and Clinical Overview. Curr Opin 
Endocrinol Metab 2002; 9: 285 – 302.
14. Issemann I and Green S. Activation of a member of the steroid 
hormone receptor superfamily by peroxisome proliferators. 
Nature (Lond) 1990; 347: 645–650.
15. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, and Wahli 
W. Control of the peroxisomal beta-oxidation pathway by a 
novel family of nuclear hormone receptors. Cell 1992; 68: 
879 – 887.
16. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, 
Mangelsdorf DJ, Umesono K, and Evans RM. Differential 
expression and activation of a family of murine peroxisome 
proliferator-activated receptors. Proc Natl Acad Sci USA 
1994; 91: 7355 – 7359. 
17. Amri EZ, Bonino F, Ailhaud G, Abumrad NA, and Grimaldi PA. 
Cloning of a protein that  ediates transcriptional effects 
of fatty acids in preadipocytes. Homology to peroxisome 
proliferator- activated receptors. J Biol Chem 1995; 270: 
2367 – 2371.
18. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, and Rodan 
GA. Identiﬁcation of a new  member of the steroid hormone 
receptor superfamily that is activated by a peroxisome 
proliferator and fatty acids. Mol Endocrinol 1992; 6:1634 
– 1641.
19. Mandard S, Muller M, and Kersten S. Peroxisome proliferator-
activated receptor alpha target genes. Cell Mol Life Sci 
2004; 61: 393 – 416.
20. Braissant O, Foufelle F, Scotto C, Dauca M, and Wahli W. 
Differential expression of peroxisome proliferator-activated 
receptors (PPARs): tissue distribution of PPAR-alpha, -
beta, and -gamma in the adult rat. Endocrinology 1996; 137: 
354 – 366.
21. Bastie C, Holst D, Gaillard D, Jehl-Pietri C, and Grimaldi PA. 
Expression of peroxisome proliferator-activated receptor 
PPARdelta promotes induction of PPARgamma and 
adipocyte differentiation in 3T3C2 ﬁbroblasts. J Biol Chem 
1999; 274:21920 – 21925.
22. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, et al. 
Growth, adipose, brain, and skin alterations resulting from 
targeted disruption of the mouse peroxisome proliferator-
activated receptor beta(delta). Mol Cell Biol 2000; 20: 5119 
– 5128.
23. Chawla A, Schwarz EJ, Dimaculangan DD, and Lazar MA. 
Peroxisome proliferator-activated receptor (PPAR) gamma: 
adipose-predominant expression and induction early in 
adipocyte differentiation. Endocrinology 1994; 135: 798 
– 800.
24. Tontonoz P, Hu E, Graves RA, Budavari AI, and Spiegelman BM. 
Mppar gamma 2: tissue-speciﬁc regulator of an adipocyte 
enhancer. Genes Dev 1994a; 8: 1224 – 1234.
25. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui 
M, Hu E, Tempst P, and Spiegelman BM. Adipocyte-speciﬁc 
transcription factor ARF6 is a heterodimeric complex of two 
nuclear hormone receptors, PPAR gamma and RXR alpha. 
Nucleic Acids Res 1994b; 22: 5628 – 5634.
26. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, et al. 
Structural organization of mouse peroxisome proliferator-
activated receptor gamma (mPPAR gamma) gene: 
alternative promoter use and different splicing yield two 
mPPAR gamma isoforms. Proc Natl Acad Sci USA 1995; 
92: 7921 – 7925. 
27. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans 
RM. Convergence of 9-cis retinoic acid and peroxisome 
proliferator signalling pathways through heterodimer 
formation of their receptors. Nature (Lond) 1992; 358: 771 
– 774.
24
The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.4-31 Print ISSN: 2085-3297, Online ISSN: 2355-9179
28. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, and Wahli W. 
Fatty acids and retinoids control lipid metabolism through 
activation of peroxisome proliferator-activated receptor-
retinoid X receptor heterodimers. Proc Natl Acad Sci USA 
1993; 90: 2160 – 2164.
29. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat 
WL, and Green S. The mouse peroxisome proliferator 
activated receptor recognizes a response element in the 5’ 
ﬂanking sequence of the rat acyl CoA oxidase gene. EMBO 
(Eur Mol Biol Organ) J 1992; 11: 433 – 439.
30. Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, and 
Desvergne B. Fluorescence imaging reveals the nuclear 
behavior of peroxisome proliferatoractivated receptor/retinoid 
X receptor heterodimers in the absence and presence of 
ligand. J Biol Chem 1995; 280: 17880 – 17890.
31. Di-Poi N, Tan NS, Michalik L, Wahli W, and Desvergne 
B.  Antiapoptotic role of PPARbeta in keratinocytes via 
transcriptional control of the Akt1 signaling pathway. Mol 
Cell 2002; 10: 721 – 733. 
32. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote 
M, Ingrey S, et l. Peroxisome proliferator-activated 
receptors and retinoic acid receptors differentially control 
the interactions of retinoid X receptor heterodimers with 
ligands, coactivators, and corepressors. Mol Cell Biol 1997; 
17: 2166 – 2176.
33. Ijpenberg AI, Jeannin E, Wahli W, and Desvergne B. Polarity and 
speciﬁc sequence requirements of peroxisome proliferator-
activated receptor (PPAR)/retinoid X receptor heterodimer 
binding to DNA. A functional analysis of the malic enzyme 
gene PPAR response element. J Biol Chem 1997; 272: 
20108 – 20117.
34. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier 
CA, et al. DNA binding properties of peroxisome proliferator-
activated receptor subtypes on various natural peroxisome 
proliferator response elements. Importance of the 5’-ﬂanking 
region. J Biol Chem 1997; 272: 25252 – 25259.
35. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, and 
Leid M. Identiﬁcation of nuclear receptor corepressor as a 
peroxisome proliferatoractivated receptor alpha interacting 
protein. J Biol Chem 1999; 274: 15901 – 15907.
36. Stanley TB, Leesnitzer LM, Montana VG, Galardi CM, Lambert 
MH, Holt JA, et al. Subtype speciﬁc effects of peroxisome 
proliferator-activated receptor ligands on corepressor 
afﬁnity. Biochemistry 2003; 42: 9278 – 9287.
37. Guan HP, Ishizuka T, Chui PC, Lehrke M, and Lazar MA. 
Corepressors selectively control the transcriptional activity 
of PPARgamma in adipocytes. Genes Dev 2005; 19: 453 
– 461.
38. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, and Cohen 
RN. The nuclear receptor corepressors NCoR and SMRT 
decrease peroxisome proliferatoractivated receptor gamma 
transcriptional activity and repress 3T3–L1 adipogenesis. J 
Biol Chem 2005; 280: 13600 – 13605. 
39. Bishop-Bailey D and Wray J. Peroxisome proliferator-activated 
receptors: a critical review on endogenous pathways for 
ligand generation. Prostaglandins Other Lipid Mediat 2003; 
71: 1 – 22.
40. Desvergne B, Michalik L, and Wahli W. Be ﬁt or be sick: 
peroxisome proliferator-activated receptors are down the 
road. Mol Endocrinol 2004; 18: 1321 – 1332.
41. Evans RM, Barish GD, and Wang YX. PPARs and the complex 
journey to obesity. Nat Med 2004; 10: 1 – 7.
42. Ferré. The Biology of Peroxisome Proloferator-Activated 
Receptors. Diabetes 2004; 53 (suppl. 1): S43 – S50.
43. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, et 
al. PPARdelta is a very low-density lipoprotein sensor in 
macrophages. Proc Natl Acad Sci USA 2003; 100: 1268 
– 1273.
44. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, 
Moller DE, et al. Lipolysis of TG-rich lipoproteins generates 
PPAR ligands: evidence for an antiinﬂammatory role for 
lipoprotein lipase. Proc Natl Acad Sci USA 2003; 100: 2730 
– 2735.
45. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, 
Ziouzenkova O, et al. High-density lipoprotein hydrolysis 
by endothelial lipase activates PPARalpha: a candidate 
mechanism for high-density lipoprotein-mediated repression 
of leukocyte adhesion. Circ Res 2006; 98: 490 – 498.
46. Bosse Y, Despres JP, Bouchard C, Perusse L, Vohl MC. The 
peroxisome proliferator-activated receptor alpha L162V 
mutation is associated with reduced adiposity. Obes Res 
2003; 11: 809 – 816. 
47. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and 
eicosanoids regulate gene expression through direct 
interactions with peroxisome proliferator-activated receptors 
alpha and gamma. Proc Natl Acad Sci U S A 1997; 94: 4318 
– 4323.
48. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann 
JM. A prostaglandin J2 metabolite binds peroxisome 
proliferator-activated receptor gamma and promotes 
adipocyte differentiation. Cell 1995; 83: 813 – 819.
49. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, 
Evans RM. 15-Deoxydelta 12, 14-prostaglandin J2 is a 
ligand for the adipocyte determination factor PPAR gamma. 
Cell 1995; 83: 803 – 812.
50. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth 
SS, Mansﬁeld TA, et al. Comprehensive messenger 
ribonucleic acid proﬁling reveals that peroxisome proliferator-
activated receptor gamma activation has coordinate effects 
on gene expression in multiple insulin-sensitive tissues. 
Endocrinology 2001; 142: 1269 – 1277.
51. Ribon V, Johnson JH, Camp HS, Saltiel AR. Thiazolidinediones 
and insulin resistance: peroxisome proliferator-activated 
receptor gamma activation stimulates expression of the 
CAP gene. Proc Natl Acad Sci U S A 1998; 95: 14751 – 
14756.
52. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, 
Kozka IJ, et al. Repeat treatment of obese mice with BRL 
49653, a new potent insulin sensitizer, enhances insulin 
action in white adipocytes: association with increased 
insulin binding and cell-surface GLUT4 as measured by 
photoafﬁnity labeling. Diabetes 1995; 44: 1087 – 1092.
53. Sfeir Z, Ibrahimi A, Amri E, Grimaldi P, Abumrad N. Regulation 
of FAT/CD36 gene expression: further evidence in support 
of a role of the protein in fatty acid binding/transport. 
Prostaglandins Leukot Essent Fatty Acids 1997; 57: 17 
– 21.
54. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis 
in ﬁbroblasts by PPAR gamma 2, a lipid-activated 
transcription factor. Cell 1994;79:1147-56. [Erratum, Cell 
1995; 80: following 957.
55. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, 
Briggs M, Deeb S, et al. PPARalpha and PPARgamma 
activators direct a distinct tissue-speciﬁc transcriptional 
response via a PPRE in the lipoprotein lipase gene. EMBO 
J 1996; 15: 5336 – 5348.
56. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. 
Coordinate regulation of the expression of the fatty acid 
transport protein and acyl-CoA synthetase genes by 
PPARalpha and PPARgamma activators. J Biol Chem 
1997; 272: 28210 – 28217.
57. Aubert J, Champigny O, Saint-Marc P, Negrel L, Collins S, 
Ricquier D, et al. Up-regulation of UCP-2 gene expression 
by PPAR agonists in preadipose and adipose cells. Biochem 
Biophys Res Commun 1997; 238: 606 – 11.
 razaL ,MC nappetS ,BC dragweN ,VM nesneJ ,Y iL ,PH nauG .85
MA. A futile metabolic cycle activated in adipocytes by 
antidiabetic agents. Nat Med 2002; 8: 1122 - 1128.
59. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized 
LDL regulates macrophage gene expression through ligand 
activation of PPARgamma. Cell 1998 93: 229 – 240.
60. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans 
RM. PPARgamma promotes monocyte/macrophage 
differentiation and uptake of oxidized LDL. Cell 1998; 93: 
241 – 252.
61. Chawla A, Boisvert WA, Lee CH, Lafﬁtte BA, Barak Y, Joseph SB, 
et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages 
is involved in cholesterol efﬂux and atherogenesis. Mol Cell 
2001; 7:  161 – 171.
62. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass 
CK. Peroxisome proliferator-activated receptor gamma 
ligands inhibit development of atherosclerosis in LDL 
receptor-deﬁcient mice. J Clin Invest 2000; 106: 523 – 531. 
63. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson 
TM, Kliewer SA. An antidiabetic thiazolidinedione is a high 
afﬁnity ligand for peroxisome proliferatoractivated receptor 
gamma (PPAR gamma). J Biol Chem 1995; 270: 12953 
– 12956.
 ʹ5
PPARs and the metabolic syndrome (Meiliana A, et al.)
Indones  Biomed J. 2009; 1(1): 4-31DOI: 10.18585/inabj.v1i1.79
64. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. 
Peroxisome-proliferator-activated receptor delta activates 
fat metabolism to prevent obesity. Cell 2003; 113: 159 
– 170.
65. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, 
et al. Fatty acid homeostasis and induction of lipid regulatory 
genes in skeletal muscles of peroxisome proliferator-
activated receptor (PPAR) alpha knock-out mice: evidence 
for compensatory regulation by PPAR delta. J Biol Chem 
2002; 277: 26089 – 26097.
66. Oliver WR Jr, Shenk JL, Snaith MR, Russel CS, Plunket KD, 
Bodkin NL,  et al. A selective peroxisome proliferator-
activated receptor delta agonist promotes reverse 
cholesterol transport. Proc Natl Acad Sci U S A 2001; 98: 
5306 – 5311.
67. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 
Suppl 736: 13 – 22.
68. Lee CH, Olson P, Evans RM. Minireview: Lipid Metabolism, 
Metabolic Disease, and Peroxisome Proliferator-Activated 
Receptors. Endocrinology 2003; 144: 2201 – 2207.
69. Desvergne B, Wahli W. Peroxisome Proliferator-Activated 
Receptors: Nuclear Control of Metabolism. Endocrinol Rev 
1999; 20: 649 – 688.
70. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, 
Gonzalez FJ, et al. Alterations in lipoprotein metabolism in 
peroxisome proliferator-activated receptor -deﬁcient mice. 
J Biol Chem 1997; 272: 27307 – 27312.
71. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et 
al. Targeted disruption of the  isoform of the peroxisome 
proliferator-activated receptor gene in mice results in 
abolishment of the pleiotropic effects of peroxisome 
proliferators. Mol Cell Biol 1995; 15: 3012 – 3022.
72. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, 
Hashimoto T, et al. Altered constitutive expression of fatty 
acid-metabolizing enzymes in mice lacking the peroxisome 
proliferator-activated receptor  (PPAR ). J Biol Chem 
1998; 273: 5678 – 5684.
73. Leone TC, Weinheimer CJ, Kelly DP. A critical role for 
the peroxisome proliferator-activated receptor alpha 
(PPARalpha) in the cellular fasting response: the PPARalpha 
null mouse as a model of fatty acid oxidation disorders. Proc 
Natl Acad Sci U S A 1999; 96: 7473 – 7478.
74. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne 
B, Wahli W. Peroxisome proliferator-activated receptor 
1999; 103:1489 – 1498.
75. Watts GF, Dimmitt SB.  Fibrates, dyslipoproteinaemia and 
cardiovascular disease. Curr Opin Lipidol 1999; 10: 561 
– 574.
76. Schultz AE, Alborn WE, Newton RK, Konrad RJ. Administration 
levels and the apolipoprotein A-V/apolipoprotein C-III ratio. 
J Lipid Res 2005; 46: 1591 – 1595.
77. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, 
Campbell M, et al. PPAR Gamma 2 Prevents Lipotoxicity 
by Controlling Adipose Tissue Expandability and Peripheral 
Lipid Metabolism. Plos Genet 2007; 3: 634 – 647.
78. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et 
al. Regulation of absorption and ABC1-mediated efﬂux of 
cholesterol by RXR heterodimers. Science 2000; 289: 1524 
– 1529.
79. Venkateswaran A, Lafﬁtte BA, Joseph SB, Mak PA, Wilpitz DC, 
Edwards PA, et al.  Control of cellular cholesterol efﬂux by 
the nuclear oxysterol receptor LXR . Proc Natl Acad Sci 
USA 2000; 97: 12097 – 12102.
80. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation 
of the ABC1 promoter by the liver X receptor/retinoid X 
receptor. J Biol Chem 2000; 75: 28240 – 28245.
81. Londos C, Brasaemle DL, Schultz CJ, Segrest JP, Kimmel AR. 
Perilipins, ADRP, and other proteins that associate with 
intracellular neutral lipid droplets in animal cells. Semin Cell 
Dev Biol 1999; 10: 51 – 58.
82. Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson 
TM, et al. TG: High – Density Lipoprotein Cholesterol 
Effects in Healthy Subjects Administered a Peroxisome 
Proliferator—Activated Receptor  Agonist. Arterioscler 
Thromb Vasc Biol 2007; 27: 359 – 365. 
83. Lee CH, Olson P, Havener A, Mehl I, Chong LW, Olefsky JM, 
et al. PPAR  Regulates Glucose Metabolism and Insulin 
Sensitivity. Proc Natl Acad Sci U S A 2006; 103: 3444 – 
3449.
84. Cock TA, Auwerx J. PPAR  Fundamental Role in Adipogenesis. 
Int Congress Series 2004; 1262: 47 – 50.
85. Rosen E.D., Walkey, C.J., Puigserver, P. & Spiegelman, B.M. 
Transcriptional regulation of adipogenesis. Genes Dev 
2000; 14: 1293 – 1307.
86. Barak Y, Nelson M, Ong E, Jones Y, Ruiz-Lozano P, Chien K , A . 
et al. PPAR  is required for placental, cardiac, and adipose 
tissue development. Mol  Cell 1999; 4: 585 – 595.
87. Rosen ED, Sarraf P, Troy A, Bradwin G, Moore K, Milstone D, et 
al. PPAR  is required for the differentiation of adipose tissue 
in vivo and in vitro. Mol Cell 1999; 4: 611 – 617.
88. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda 
K, et al. PPAR  mediates high-fat diet-induced adipocyte 
hypertrophy and insulin resistance. Mol Cell 1999; 4: 597 
– 609.
89. Agarwal AK & Garg A. A novel heterozygous mutation in 
peroxisome proliferator activated receptor-  gene in a 
patient with familial partial lipodystrophy. J Clin Endocrinol 
Metab 2002; 87:  408 – 411.
90. Hegele RA, Cao H, Frankowski C, Mathews ST & Leff T. PPARG 
F388L, a transactivation-deﬁcient mutant, in familial partial 
lipodystrophy. Diabetes 2002; 51: 3586 – 3590.
91. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, 
et al. Human metabolic syndrome resulting from dominant-
negative mutations in the nuclear receptor peroxisome 
proliferator-activated receptor- . Diabetes 2003; 52: 910 
– 917.
92. Wu Z, Rosen E, Brun R, Hauser S, Adelmant A, Troy A, et 
al. Cross-regulation of C/EBP and PPAR  controls the 
transcriptional pathway of adipogenesis and insulin 
sensitivity. Mol Cell 1999; 3: 151 – 158.
93. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez 
FJ, et al. C/EBPalpha induces adipogenesis through PPAR : 
a uniﬁed pathway. Genes Dev 2002; 16: 22 – 26.
94. MacDougald OA, and Mandrup S. Adipogenesis: forces that tip 
the scales. Trends Endocrinol Metab 2002; 13: 5 – 11.
95. Frohnert BI, Hui TY, and Bernlohr DA. Identiﬁcation of a functional 
peroxisome proliferator-responsive element in the murine 
fatty acid transport protein gene. J Biol Chem 1999; 274: 
3970 – 3977.
96. Chui, PC, Guan HP, Lehrke M, and Lazar M.A. PPARgamma 
regulates adipocyte cholesterol metabolism via oxidized 
LDL receptor 1. J Clin Invest 2005; 115: 2244 – 2256.
97. Tontonoz P, Hu E, Devine J, Beale EG, and Spiegelman BM. 
 eht fo noisserpxe esopida setaluger 2 ammag RAPP
phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 
1995; 15: 351 – 357.
98. Tordjman J, Chauvet G, uette J, Beale EG, Forest C, and 
Antoine B. Thiazolidinediones block fatty acid release by 
inducing glyceroneogenesis in fat cells. J Biol Chem. 2003; 
278: 18785 – 18790.
99. Hibuse T, Maeda N, Funahashi T, Yamamoto K, Nagasawa A, 
Mizunoya W, et al. Aquaporin 7 deﬁciency is associated 
with development of obesity through activation of adipose 
26
The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.4-31 Print ISSN: 2085-3297, Online ISSN: 2355-9179
 glycerol kinase. Proc Natl Acad Sci USA 2005; 102: 10993 
– 10998.
100. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et 
al. Troglitazone increases the number of small adipocytes 
without the change of white adipose tissue mass in obese 
Zucker rats. J Clin. Invest 1998; 101: 1354 – 1361.
101. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, 
Leszyk J, Straubhaar  J, et al Mitochondrial remodeling in 
adipose tissue associated with obesity and treatment with 
rosiglitazone. J Clin Invest 2004; 114: 1281 – 1289.
102. Lehrke M, Lazar MA. The Many Faces of PPAR . Cell 2005; 
123: 993 – 999.
103. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima 
J, Komeda K, et al. The mechanisms by which both 
heterozygous peroxisome proliferator-activated receptor 
 (PPAR ) deﬁciency and PPAR  agonist improve insulin 
resistance. J Biol Chem 2001;  276: 41245 – 41254.
104. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block 
tumor necrosis factor- -induced inhibition of insulin 
signaling. J Cli. Invest 1997; 100: 1863 – 1869. 
105. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright 
CM, et al. The hormone resistin links obesity to diabetes. 
Nature 2001; 409: 307 – 312.
106. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived 
resistin and gut-derived resistin-like molecule-  selectively 
impair insulin action on glucose production. J Clin Invest 
2003; 111: 225 – 300.
107. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. 
Endogenous glucose production is inhibited by the adipose-
derived protein Acrp30. J Clin Invest 2001; 108: 1875 
– 1881.
108.  Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The 
adipocytesecreted protein Acrp30 enhances hepatic insulin 
action. Nat Med 2001; 7: 947 – 953.
109. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, 
et al. The fat-derived hormone adiponectin reverses insulin 
resistance associated with both lipoatrophy and obesity. Nat 
Med 2001; 7: 941 – 946.
110. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, 
et. Adiponectin stimulates glucose utilization and fatty-acid 
oxidation by activating AMP-activated protein kinase. Nat 
Med 2002; 8: 1288 – 1295.
111. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et 
al. Cloning of adiponectin receptors that mediate antidiabetic 
metabolic effects. Nature 2003; 423: 762 – 769.
112. Yamauchi T, Waki H, Kamin J, Murakami K, Motojima K, 
Komeda K, et al. Inhibition of RXR and PPAR  Ameliorates 
Diet – Induced Obesity and Type 2 Diabetes. J Clin Invest 
2001; 108: 1001 – 1013.
113. Zhang B, Berger J, Hu E, Szalkowski D, White – Carrington S, 
Spielgman BM, et al.  Negative Regulation of Peroxisome 
Proliferator – Activated Receptor -  Gene Expression 
Contributes to the Antiadipogenic Effects of Tumor Necrosis 
Factor – . Mol Endocrinol 1996; 10: 1457 – 1466.
114. White, M.F. Insulin signaling in health and disease. Science 
2003; 302: 1710 – 1711.
115. Minami A, Iseki M, Kishi K, Wang M, Ogura M, Furukawa N, et 
al. Increased insulin sensitivity and hypoinsulinemia in APS 
knockout mice. Diabetes 2003; 52: 2657 – 2665.
116. Duan C, Yang H, White MF, Rui L. Disruption of the SH2-B 
gene causes agedependent insulin resistance and glucose 
intolerance. Mol Cell Biol 2004; 24: 7435 – 7443. 
117. Molero JC, Jensen TE, Withers PC, Couzens M, Herzog 
, Thien CBF, et al. c-Cbl–deﬁcient mice have reduced 
adiposity, higher energy expenditure and improved 
peripheral insulin action. J Clin Invest 2004; 114: 1326 – 
1333.
118. Bard-Chapeau EA, Hevener AL, Long S, Zhang EE, Olefsky JM, 
Feng GS. Deletion of Gab1 in the liver leads to enhanced 
glucose tolerance and improved hepatic insulin action. Nat 
Med 2005; 11: 567 – 571.
119. Hosomi Y, Ogawa KS, Matsuba H, Yoshida M, Okada Y, Yokono 
K, et al. Characterization of a 60-kilodalton substrate of 
the insulin receptor kinase. J Biol Chem 1994; 269: 11498 
– 11502.
120. Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi 
R, Stillman B,  et al. p62dok: a constitutively tyrosine-
phosphorylated, GAP-associated protein in chronic 
myelogenous leukemia progenitor cells. Cell 1997; 88: 197 
– 204.
121. Yamanashi Y, Baltimore D. Identiﬁcation of the Abl- and 
rasGAP-associated 62-kDa protein as a docking protein, 
Dok. Cell 1997; 88: 205 – 211.
122. Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, Inoue 
H, et al. Dok1 Mediates High – Fat Diet – Induced Adipocyte 
Hypertrophy and Onesity Through Modulation of PPAR -  
Phosphorylation. Nat Med 2008; 14: 188 – 193.
123. Cohen RN. Nuclear Receptor Corepressors and PPAR . NRS 
2006; 4: 1 – 4.
124. Wu Z, Andersson U, Zhang C, Adelmant G, Mootha V, Troy 
A, et al. Mechanisms controlling mitochondrial biogenesis 
and respiration through the thermogenic coactivator PGC-1. 
Cell 1999; 98: 115 – 124.
125. Puigserver, P. Wu Z, Park CW, Graves R, Wright M, Spiegelman 
BM. A cold-inducible coactivator of nuclear receptors linked 
to adaptive thermogenesis. Cell 1998; 92: 829 – 839.
126. Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, Fujiu K, et al. 
SUMOylation of Krppel – like Transcription Factor 5 Acts 
As A Molecular Switch in Transcriptional Programs of Lipid 
Metabolism Involving PPAR - . Nat Med 2008; 14: 656 
– 666. 
127. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GEO. 
The peroxisome proliferator–activated receptor b d agonist, 
GW501516, regulates the expression of genes involved in 
lipid catabolism and energy uncoupling in skeletal muscle 
cells. Mol Endocrinol 2003; 17: 2477 – 2493.
128. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Jamura H, Ikeda 
Y, et al. Activation of peroxisome proliferator–activated 
receptor d induces fatty acid b-oxidation in skeletal muscle 
and attenuates metabolic syndrome. Proc Natl Acad Sci 
USA 2003; 100: 15924 – 15929.
129. Krey G, Braissant O, L Horset F, Kalkhoven E, Perroud M, 
Parker MG, et al. Fatty acids, eicosanoids, and hypolipidemic 
agents identiﬁed as ligands of peroxisome proliferator-
activated receptors by coactivator-dependent receptor 
ligand assay. Mol Endocrinol 1997; 11: 779 – 791.
130. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, 
et al. Interleukin-4-dependent production of PPAR-  ligands 
in macrophages by 12 15-lipoxygenase. Nature 1999; 400: 
378 – 382.
131. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass 
CK, et al. Regulation of cytokine expression by ligands of 
peroxisome proliferator activated receptors. J Immunol 
2002; 168: 2795 – 2802.
132. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. 
PPARgamma and PPARdelta negatively regulate speciﬁc 
subsets of lipopolysaccharide and IFN-gamma target genes 
in macrophages. Proc Natl Acad Sci U S A 2003; 100: 6712 
– 6717. 
133. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The 
peroxisome proliferator-activated receptor-  is a negative 
regulator of macrophage activation. Nature 1998; 391: 79 
– 82. 
134. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd 
Z, et al. Activation of proliferatoractivated receptors  
 ʹ7
PPARs and the metabolic syndrome (Meiliana A, et al.)
Indones  Biomed J. 2009; 1(1): 4-31DOI: 10.18585/inabj.v1i1.79
 and  induces apoptosis of human monocytederived 
macrophages. J Biol Chem. 1998; 273: 25573 – 25580.
135. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez 
FJ, Wahli W. The PPAR -leukotriene B4 pathway to 
inﬂammation control. Nature 1996; 384: 39 – 43.
136. Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM,  Gonzalez 
FJ, et al. Effect of peroxisome proliferator-activated receptor 
alpha activators on tumor necrosis factor expression in mice 
during endotoxemia. Infect Immun 1999; 67: 3488 – 3493. 
137. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, 
Hedrick CC, et al. Role for peroxisome proliferator-activated 
receptor alpha in oxidized phospholipid-induced synthesis 
of monocyte chemotactic protein-1 and interleukin-8 by 
endothelial cells. Circ Res 2000; 87: 516 – 521.
138. Ricote M, Valledor AF, Glass CK. Decoding Transcriptional 
Programs Regulated by PPARs and LXRs in the 
Macrophage: Effects on Lipid Homeostasis, Inﬂammation, 
and Atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 
24: 230 – 239.
139. Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-
reactive protein–mediated monocyte chemoattractant 
protein-1 induction in human endothelial cells by 
antiatherosclerosis drugs. Circulation 2001; 103: 2531 
– 2534. 
140. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, 
Mochizuki S. Fenoﬁbrate effectively reduces remnants and 
small dense LDL and increases HDL particle number in 
hyperTGmic men—a nuclear magnetic resonance study. J 
Atheroscler Thromb. 2004; 11: 278  – 285.
141. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. 
Efﬁcacy of fenoﬁbrate and simvastatin on endothelial 
function and inﬂammatory markers in patients with 
combined hyperlipidemia: relations with baseline lipid 
proﬁles. Atherosclerosis 2003; 170: 315 – 323.
142. Han SH, Quon MJ, Koh KK. Beneﬁcial Vascular and Metabolic 
Effects of Peroxisome Proliferator – Activated Receptor –  
Activators. Hypertension 2005; 46: 1086 – 1092. 
143. Teissier E, Nohara A, Chonetti G, Paumelle R, Cariou B, Fruchart 
JC, et al. Peroxisome proliferator–activated receptor  
induces NADPH oxidase activity in macrophages, leading 
to the generation of LDL with PPAR-  activation properties. 
Circ Res 2004; 95: 1174 – 1182.
144. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, 
Gillotre-Taylor K, et al. Scavenger receptors, oxidized LDL, 
and atherosclerosis. Ann N Y Acad Sci. 2001;9 47: 214 
– 222; discussion 222 – 223.
145. Devchand PR, Ziouzenkova O, Plutzky J. Oxidative Stress and 
Peroxisome Proliferator – Activated Receptors. Reversing 
or Curse? Circ Res 2004; 95: 1137 – 1139.
146. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. 
PPAR-gamma dependent and independent effects on 
macrophage-gene expression in lipid metabolism and 
inﬂammation. Nature Med 2001;  7: 48 – 52.
147. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit 
production of monocyte inﬂammatory cytokines. Nature 
1998; 391: 82 – 86.
148. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. 
Expression of the peroxisome proliferatoractivated receptor 
g (PPARg) in human atherosclerosis and regulation in 
macrophages by colony stimulating factors and oxidized 
low density lipoproteins. Proc Natl Acad Sci USA 1998; 95: 
7614 – 7619. 
149. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, 
Altshuler D, et al. The role of PPAR-gamma in macrophage 
differentiation and cholesterol uptake. Nature Med 2001; 7: 
41 – 47.
150. Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, 
Detmers PA,Somers EP, et al. Activation of peroxisome 
proliferator-activated receptor gamma does not inhibit IL-6 or 
TNF-alpha responses of macrophages to lipopolysaccharide 
in vitro or in vivo. J Immunol 2000; 164: 1046 – 1054.
151. Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K. 
Prostaglandins up-regulate vascular endothelial growth 
factor production through distinct pathways in differentiated 
U937 cells. Biochem Biophys Res Commun 2000; 273: 485 
– 491.
152. Moore KJ, Fitzgerald ML, Freeman MW. Peroxisome Proliferator 
– Activated Receptors in Macrophage Biology: Friend or 
Foe? Curr Opin Lipidol 2001; 12: 519 – 527.
153. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-
activated receptors (PPARs): nuclear receptors at the 
crossroads between lipid metabolism and inﬂammation. 
Inﬂamm Res 2000; 49: 497 – 505.
154. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, 
Chandraratna RA, et al. Peroxisome proliferator-activated 
receptor and retinoid X receptor ligands inhibit monocyte 
chemotactic protein-1-directed migration of monocytes. Eur 
J Pharmacol 2000; 401: 259 – 270.
155. Tanaka T, Fukunaga Y, Itoh H, Doi K, Yamashita J, Chun TH, et 
al. Therapeutic potential of thiazolidinediones in activation 
of peroxisome proliferator-activated receptor gamma for 
monocyte recruitment and endothelial regeneration. Eur J 
Pharmacol 2005; 508: 255 – 265.
156. Rigamonti E, Fontaine C, Lefebvre B, Duhem C, Lefebvre P, 
Marx N, et al. Induction of CXCR2 Receptor by Peroxisome 
Proliferator – Activated Receptor  in Human Macrophages. 
Arterioscler Thromb Vasc Biol 2008; 28: 932 – 939.
157. Marx N, Bourcier T, Sukhova GK, LibbyP, Plutzky J. PPARgamma 
activation in human endothelial cells increases plasminogen 
activator inhibitor type-1 expression: PPARgamma as a 
potential mediator in vascular disease. Arterioscler Thromb 
Vasc Biol 1999; 19: 546 – 551.
158. Plutzky J. Peroxisome Proliferator-Activated Receptors in 
Endothelial Cell Biology. Curr Opin Lipidol 2001; 12: 511.
159. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov 
S, Hart CM. Peroxisome Proliferator-Activated Receptors 
-  Ligands Regulate Endothelial Membrane Superoxide 
Production. Am J Physiol Cell Physiol 2005; 288: C899 
– C905.
160. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada 
K. Vascular Inﬂammation Is negatively Autoregulated by 
Interaction Between CCAAT/Enhancer – Binding Protein -  
and Peroxisome Proliferator – Activated Receptor - . Circ 
Res 2002; 91: 427 – 433.
161. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert W, Evans EM. 
Transkriptional Repression of Atherogenic Inﬂammation: 
Modulation by PPAR . Science 2003; 302: 453 – 457.
162. Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong 
LW, et al. Peroxisome Proliferator-Activated Receptor  
Promotes Very Low – Density Lipoprotein – Derived Fatty 
Acid Catabolism in teh macrophage. Proc Natl Acad Sci U 
S A 2006; 103: 2434 – 2439.
163. Fan Y, Wang Y, Tang Z, Zhang H, Qin X, Zhu Y, et al. Supression 
pro-Inﬂammatory Adhesion Molecules by PPAR-  in Human 
Vascular Endothelial Cells. Arteriol Thromb Vasc Biol 2008; 
28: 315 – 321.
164. Kim HJ, Ham SA, Kim SU, Hwang JY, Kim JH, Chang KC, et 
al. Transforming Growth factor - 1 Is a Molecular Target for 
the Peroxisome Proiliferator – Activated Receptor . Circ 
Rei 2008; 102: 193 – 200.
165. Yagil C and Yagil Y. Peroxisome Proliferator – Activated 
Receptors – . Friend or Foe? Hypertension 2007; 50: 847 
– 850.
166. Tordjman K, Semenkovich CF, Coleman T, Yudovich R, Bak S, 
Osher E, et al. Absence of peroxisome proliferatoractivated 
28
The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.4-31 Print ISSN: 2085-3297, Online ISSN: 2355-9179
receptor-  abolishes hypertension and attenuates atherosclerosis in 
 :05 ;7002 noisnetrepyH .esuom evisnetrepyh abukusT eht
945 – 951.
167. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome Proliferator 
– Activated Receptors and Atherogenesis. Regulators of 
Gene Expression in Vascular Cells. Circ Res 2004; 94: 1168 
– 1178.
168. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt 
S, et al. Reduction of atherosclerosis by the peroxisome 
proliferator-activated receptor agonist fenoﬁbrate in mice. J 
Biol Chem 2002; 277: 48051 – 48057.
169. Vosper H, Khoudoli GA, Graham TL, Palmer CNA. Peroxisome 
proliferator-activated agonists, hyperlidaemia, and 
atherosclerosis. Pharm Ther 2002; 95: 47 – 62.
170. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Schiffrin 
EL. PPAR  activator effects on ANG II-induced vascular 
oxidative stress and inﬂammation. Hypertension 2002; 40: 
866 – 871.
171. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. 
Effect of peroxisome proliferator-activated receptor-  and -  
activators on vascular remodeling in endothelin-dependent 
hypertension. Arterioscler Thromb Vasc Biol 2003; 23: 45 
– 51.
172. Banks T, Oyekan A. Peroxisome proliferator-activated receptor 
a activation attenuated angiotensin type 1-mediated but 
enhanced angiotensin type 2-mediated hemodynamic 
effects to angiotensin II in the rat. J Hypertension 2008; 26: 
468 – 477.
173. Granger JP. Endothelin. Am J Physiol Regul Integr Comp 
Physiol 2003; 285: R298–R301.
174. Rubanyi GM, Polokoff MA. Endothelins: molecular 
biology, biochemistry, pharmacology, physiology, and 
pathophysiology. Pharmacol Rev 1994; 46: 325 – 415.
175. Pollock DM. Renal endothelin in hypertension. Curr Opin 
Nephrol Hypertens 2000; 9: 157 – 164.
176. Roman RJ. P-450 metabolites of arachidonic acid in the control 
of cardiovascular function. Physiol Rev 2002; 82: 131 
– 185.
177. Alonso-Galicia M, Frohlich B, Roman RJ. Induction of P4504A 
activity improves pressure-natriuresis in Dahl S rats. 
Hypertensio. 1998; 31: 232 – 236.
178. Roman RJ, Ma YH, Frohlich B, Markham B. Cloﬁbrate prevents 
the development of hypertension in Dahl salt-sensitive rats. 
Hypertension 1993; 21: 985 – 988.
179. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, Roman RJ. 
Inhibition of the formation of EETs and 20-HETE with 1-
aminobenzotriazole attenuates pressure natriuresis. Am J 
Physiol Regul Integr Comp Physiol 2004; 287: R58 – R68.
180. Zhang YB, Magyar CE, Holstein-Rathlou NH, McDonough AA. 
The cytochrome P-450 inhibitor cobalt chloride prevents 
inhibition of renal Na+,K+-ATPase and redistribution of 
apical NHE-3 during acute hypertension. J Am Soc Nephrol 
1998; 9: 531 – 537.
181. Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE 
formation promote salt-sensitive hypertension in rats. 
Hypertension 2003; 42: 669 – 673. 
182. Hoagland KM, Flasch AK, Dahly-Vernon AJ, dos Santos EA, 
Knepper MA, Roman RJ. Elevated BSC-1 and ROMK 
expression in Dahl saltsensitive rat kidneys. Hypertension 
2004; 43: 860 – 865.
183. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-
lowering agents in the Dahl salt-sensitive rat. Hypertension 
1998; 31: 225 – 231.
184. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. 
Peroxisome Proliferator-Activated Receptor-  Activation 
Reduces Salt-Dependent Hypertension During Chronic 
Endothelin B Receptor Blockade. Hypertension 2005; 46: 
366 – 371.
185. Subramanian S, DeRosa MA, Bernal – Mizrachi C, Laffely N, 
Blood Pressure and Does Not Correct Glucocorticoid 
– Induced Insulin Resistance in Humans. Am J Physiol 
Endocrinol Metab 2006; 291: E1365 – E1371.
186. Weatherford ET, Itani H, Keen HL, Sigmund CD. Is Peroxisome 
Proliferator-Activated Receptor-  a New “Pal” of Renin? 
Hypertension 2007; 50: 844 – 846.
187. Shi Q, Gross KW, Sigmund CD. Retinoic acid-mediated 
activation of the mouse renin enhancer. J Biol Chem 2001; 
276: 3597 – 3603. 
188. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P. 1,25-
Dihydroxyvitamin D3 is a negative endocrine regulator of 
the renin-angiotensin system. J Clin Invest 2002; 110: 229 
– 238.
189. Sugawara A, Takeuchi K, runo A, Ikeda Y, Arima S, Kudo 
M, et al. Transcriptional suppression of type 1 angiotensin 
II receptor gene expression by peroxisome proliferator-
activated receptor-gamma in vascular smooth muscle cells. 
Endocrinology. 2001; 142: 3125 – 3134.
190. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. 
Clinical management of metabolic syndrome: report of the 
Am Heart Association National Heart, Lung, and Blood 
Institute Am Diabetes Association conference on scientiﬁc 
issues related to management. Circulation 2004; 109: 551 
– 556.
191. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, 
Soffer D, et al. Effects of Pioglitazone on Lipoproteins, 
Inﬂammatory Markers, and Adipokines in Nondiabetic 
Patients with Metabolic Syndrome Arterioscler Thromb 
Vasc Biol 2006; 26: 182 – 188.
192. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et 
al. Cardiovascular Morbidity and Mortality Associated with 
the metabolic Syndrome. Diab Care 2001; 24: 683.
193. Stern MP, Williams K, Gonzalez – Villalpando C, Hunt KJ, 
Haffner SM. Does the Metabolic Syndrome Improve 
Indentiﬁcation of Individuals at Risk of Type 2 Diabetes and 
 or Cardiovascular Disease? Diab Care 2004; 27: 2676 
– 2681.
194. Cignarella A, Bellosta S, Corsini A, Bolego C. Hypolipidemic 
Therapy for The Metabolic Syndrome. Pharmacol Res 
2006; 53: 492 – 500.
195. Semple RK, Chatter ee VK, O Rahilly S. PPAR  and human 
metabolic disease. J Clin Invest 2006; 116: 581 – 589. 
196. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic 
syndrome among S adults: ﬁndings from the third National 
Health and Nutrition Examination Survey. JAMA 2002; 287: 
356 – 359.
197. Szapary PO, Rader DJ. The TG-high-density lipoprotein axis: 
an important target of therapy? Am Heart J 2004; 148: 211 
– 221.
198. Barish GD, Narkar VA, Evans RM. PPAR : A Dagger in The 
Heart of The Metabolic Syndrome. J Clin Invest 2006; 116: 
590 – 597.
199. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. 
Lancet 2005; 365: 1415 – 1428.
200. Grundy SM. Point: the metabolic syndrome still lives. Clin 
Chem 2005; 51: 1352 – 1354. 
201. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J 
Clin Endocrinol Metab 2004; 89: 2548 – 2556. 
202. Frayn KN: Adipose tissue as a buffer for daily lipid ﬂux. 
Diabetologia 2002; 45: 1201 – 1210.
203. Perseghin G: Muscle lipid metabolism in the metabolic 
syndrome. Curr Opin Lipidol 2005; 16: 416 – 420.
 ʹ9
PPARs and the metabolic syndrome (Meiliana A, et al.)
Indones  Biomed J. 2009; 1(1): 4-31DOI: 10.18585/inabj.v1i1.79
204. Yki-Jarvinen H: Fat in the liver and insulin resistance. Ann Med 
2005; 37: 347 – 356.
205. Heilbronn L, Smith SR, Ravussin E: Failure of fat cell 
proliferation, mitochondrial function and fat oxidation results 
in ectopic fat storage, insulin resistance and type II diabetes 
mellitus. Int J Obes Relat Metab Disord 2004; 28 (Suppl 4): 
S12 – S21.
206. Goodpaster BH, Wolf D: Skeletal muscle lipid accumulation 
in obesity, insulin resistance, and type 2 diabetes. Pediatr 
Diabetes 5:219 –226, 2004 6. Petersen KF, Shulman GI: 
Etiology of insulin resistance. Am J Med 2006; 119: S10 
– S16.
207. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. 
Obesity, Peroxisome Proliferator-Activated Receptor, and 
Atherosclerosis in Type 2 Diabetes. Arteriocler Throm Vasc 
Biol 2006; 26: 28 – 40.
208. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct 
and indirect effects of tumor necrosis factor-alpha. Cytokine 
Growth Factor Rev 2003; 14: 447 – 455.
209. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai 
H, et al. Pathophysiological role of leptin in obesity-related 
hypertension. J Clin Invest 2000; 105: 1243 – 1252.
210. Cassis LA, Saye J, Peach MJ. Location and regulation of rat 
angiotensinogen messenger RNA. Hypertension 1988; 11: 
591 – 596. 
211. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian 
S, et al. Expression of plasminogen activator inhibitor-1 in 
human adipose tissue: a role for TNF-alpha? Atherosclerosis 
1999; 143: 81 – 90.
212. Lijnen HR. Pleiotropic functions of plasminogen activator 
inhibitor-1. J Thromb Haemost 2005; 3: 35 – 44.
213. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui 
J, et al. Disruption of adiponectin causes insulin resistance 
and neointimal formation. J Biol Chem 2002; 277:  25863 
– 25866.
214. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki 
K, et al. Globular adiponectin protected ob/ob mice from 
diabetes and ApoE-deﬁcient mice from atherosclerosis. J 
Biol Chem 2003; 278: 2461 – 2468.
215. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama 
H, et al. Adiponectin, an adipocytederived plasma protein, 
inhibits endothelial NF-kappaB signaling through a cAMP-
dependent pathway. Circulation 2000; 102: 1296 – 1301.
216. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, 
Kishimoto K, et al. Visfatin: a protein secreted by visceral 
fat that mimics the effects of insulin. Science 2005; 307: 
426 – 430.
217. Rise´rus U, Sprecher D, Johnson T, Olson E, Hirschberg S, 
Liu A, et al. Activation of Peroxisome Proliferator–Activated 
Receptor (PPAR)  Promotes Reversal of Multiple Metabolic 
Abnormalities, Reduces Oxidative Stress, and Increases 
Fatty Acid Oxidation in Moderately Obese Men. Diabetes 
2008; 57: 332 – 229.
218. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, 
et al. Increased CD36 protein as a response to defective 
insulin signaling in macrophages. J Clin Invest 2004; 113: 
764 – 773. 
219. Shoelson SE, Lee J, Goldﬁne AB. Inﬂammation and insulin 
resistance. J Clin Invest 2006;  116: 1793 – 1801.
220. Hotamisligil GS. Inﬂammation and metabolic disorders. Nature 
2006; 444: 860 – 867.
221. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, 
Ferrante, Jr AW.. Obesity is associated with macrophage 
accumulation in adipose tissue. J Clin Invest 2003; 112: 
1796 – 1808.
222. Xu, H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. 
Chronic inﬂammation in fat plays a crucial role in the 
development of obesity-related insulin resistance. J Clin 
Invest 2003; 112: 1821 – 1830.
223. Odegaard Ricardo-Gonzalez RR, Goforth MH, Morel CR, 
Subramanian V, Mukundan L, Eagle AR,  et al. Macrophage-
speciﬁc PPAR  controls alternative activation and improves 
insulin resistance. Nature 2007; 447: 1116 – 1121.
224. Brown JD, Plutzky JP. Peroxisome Proliferator-Activated 
Receptor as Transcriptional Nodal Points and Therapeutic 
targets. Circulation 2007; 115: 518 – 533.
225. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, 
Franklin BA, et al. Diagnosis and Management of the 
Metabolic Syndrome – an American Heart Association/
National Heart, lung, and Blood Institute Scientiﬁc 
Statement. Circulation 2005; 112: 2735 – 2752.
226. Chinnetti – Gbaguidi G, Fruchart JC, Staels B, Role of PPAR 
family of Nuclear Receptors in the Regulation of Metabolic 
and Cardiovascular Homeostasis: New Approach to 
Therapies. Curr Opin Pharmacol 2005; 5: 177 – 183.
227. Tordjman K, Bernal – Mizrachi C, Zemany L, Weng S, Feng C, 
Zhang F, Lene TC, et al. PPAR  Deﬁciency Reduces Insulin 
Resistance And Atherosclerosis in apoE – null Mice. J Clin 
Invest 2001; 107: 1025 – 1034.
228. Berger JP. Akiyama TE, Meinke PT. PPARs: Therapeutic 
Targets for Metabolic Disease. Trends Pharmacol Sci 2005; 
26: 244 – 251.
229. Maragoudakis ME, Hankin H. On the mode of action of lipid-
lowering agents. V. Kinetics of the inhibition in vitro of rat 
acetyl coenzyme A carboxylase. J Biol Chem 1971; 246: 
348 – 358.
230. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf 
E, Fruchart JC. Mechanism of action of ﬁbrates on lipid and 
lipoprotein metabolism. Circulation 1998; 98: 2088 – 2093. 
231. Heller F, Harvengt C. Effects of cloﬁbrate, bezaﬁbrate, 
fenoﬁbrate and probucol on plasma lipolytic enzymes in 
normolipaemic subjects. Eur J Clin Pharmacol 1983; 25: 57 
– 63.
232. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, 
Dallongeville J, et al/ Fibrates downregulate apolipoprotein 
C-III expression independent of induction of peroxisomal 
acyl coenzyme A oxidase. A potential mechanism for the 
hypolipidemic action of ﬁbrates. J Clin Invest 1995; 95: 705 
– 712.
233. Malmendier CL, Delcroix C. Effects of fenoﬁbrate on high and 
low density lipoprotein metabolism in heterozygous familial 
hypercholesterolemia. Atherosclerosis 1985; 55: 161 
– 169. 
234. Mellies MJ, Stein EA, Khoury P, Lamkin G, Glueck CJ. Effects of 
fenoﬁbrate on lipids, lipoproteins, and apolipoproteins in 33 
subjects with primary hypercholesterolemia. Atherosclerosis 
1987; 63: 57 – 64.
235. Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, 
McGinnis  BM. Effect of fenoﬁbrate treatment on plasma 
lipoprotein lipids, highdensity lipoprotein cholesterol 
subfractions, and apolipoproteins B, AI, AII, and E. Am J 
Med 1987; 83: 75 – 84. 
236. Bard JM, Parra HJ, Camare R, Luc G, Ziegler O, Dachet C, et 
l. A multicenter comparison of the effects of simvastatin and 
fenoﬁbrate therapy in severe primary hypercholesterolemia, 
with particular emphasis on lipoproteins deﬁned by their 
apolipoprotein composition. Metabolism 1992; 41: 498 
– 503.
237. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra 
IP, et al. PPAR-  and PPAR-  activators induce cholesterol 
removal from human macrophage foam cells through 
stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53 
– 58.
238. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison 
JW, et al. Differential Inhibition of Macrophage Foam – Cell 
͵Ͳ
The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.4-31 Print ISSN: 2085-3297, Online ISSN: 2355-9179
Formation and Atherosclerosis in Mice by PPAR , / , and . J Clin 
Invest 2004; 114: 1564 – 1576.
239. Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, Arai H, 
Kozarsky KF, Altayo M, Miquel JF, Luc G, Clavey V, Staels 
B, Rigotti Aet a;. Fibrates down-regulate hepatic scavenger 
receptor class B type I protein expression in mice. J Biol 
Chem 2003; 278:7 884 – 7890.
240. Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima 
M, et al. The effects of statin and ﬁbrate on lowering small 
dense LDL- cholesterol in hyperlipidemic patients with type 
2 diabetes. J Atheroscler Thromb 2007; 14: 128 – 132.
241. Barter PJ, Rye KA. Is There A Role for Fibrates in the 
Management of Dyslipidemia in the Metabolic Syndrome? 
Arterioscler Thromb Vasc Biol 2008; 28: 39 – 46.
242. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. 
Annu Rev Nutr 2002; 22: 167 – 197.
243. Miyazaki Y, Mahankali A, Matsuda M, Jean H, Kenneth  C, 
Mandarino LJ, et al. Effect of pioglitazone on abdominal fat 
distribution and insulin sensitivity in type 2 diabetic patients. 
J Clin Endocrinol Metab 2002; 87: 2784 – 2791.
244. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda H, 
Nagaretani H, et al. Diet-induced insulin resistance in mice 
lacking adiponectin/ACRP30. Nat Med 2002; 8: 731 – 737.
245. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda 
N, et al. Role of adiponectin in preventing vascular stenosis: 
the missing link of adipo-vascular axis. J Biol Chem 2002; 
277: 37487 – 37491.
246. Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: 
summary and future prospects. Mol Cell Biochem 1998; 
182: 169 – 175.
247. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright 
CM, et al. The hormone resistin links obesity to diabetes. 
Nature 2001; 409: 307 – 312.
248. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, 
Moller DE, Wright SD, et al. Peroxisome proliferator-
activated receptor gamma ligands inhibit adipocyte 
11betahydroxysteroid dehydrogenase type 1 expression 
and activity. J Biol Chem 2001; 276: 12629 – 12635.
249. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, 
Seckl JR, Flier JS. A transgenic model of visceral obesity 
and the metabolic syndrome. Science 2001; 294: 2166 
– 2170.
250. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, 
Kishida K, et al. PPARgamma ligands increase expression 
and plasma concentrations of adiponectin, an adipose-
derived protein. Diabetes 2001; 50: 2094 – 2099.
251. Walker BR. How will we know if 11betahydroxysteroid 
dehydrogenases are important in common diseases. Clin 
Endocrinol (Oxf ) 2000; 52: 401 – 402.
252. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, 
Kochar A, et a;. Effects of Rosglitazone of Lipids, Adipokines, 
and Inﬂammatory Markers in Nondiabetic Patients With 
Low High – Density Lipoprotein Cholesterol and Metabolic 
Syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 624 
– 630.
253. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression 
of adiponectin receptors in human macrophages and 
regulation by agonists of the nuclear receptors PPARalpha, 
PPARgamma, and LXR. Biochem Biophys Res Commun 
2004; 314: 151 – 158.
254. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, Nyman T, 
Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and 
metformin on liver fat content, hepatic insulin resistance, 
insulin clearance, and gene expression in adipose tissue 
in patients with type 2 diabetes. Diabetes 2004; 53: 2169 
– 2176. 
255. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm 
EB. Plasma adiponectin levels and risk of myocardial 
infarction in men. JAMA 2004; 291: 1730 – 1737. 
256. Junga HS, Younb B-S, Choa YM, Yub K-Y, Parkb HJ, Shina 
CS, et al. The effects of rosiglitazone and metformin on the 
plasma concentrations of resistin in patients with type 2 
diabetes mellitus. Metabolism 2005; 54: 314 – 320. 
257. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader 
DJ. Resistin is an inﬂammatory marker of atherosclerosis in 
humans. Circulation 2005; 111: 932 – 939.
258. Lehrke M, Reilly M, Millington S, Iqbal N, Rader D, and Lazar 
MA. An inﬂammatory cascade leading to hyperresistinemia 
in humans. PLoS Med 2004; 1: 161 – 168.
259. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, 
Freed MI. Effect of rosiglitazone treatment on nontraditional 
markers of cardiovascular disease in patients with type 2 
diabetes mellitus. Circulation 2002; 106: 679 – 684.
260. Sidhu JS, Cowan D, Kaski J-C. The effects of rosiglitazone, a 
peroxisome proliferator-activated receptor-gamma agonist, 
on markers of endothelial cell activation, C-reactive protein, 
and ﬁbrinogen levels in non-diabetic coronary artery disease 
patients. J Am Coll Cardiol 2003; 42: 1757 – 1763.
261. Wang T-D, Chen W-J, Lin J-W, Chen M-F, Lee Y-T. Effects of 
rosiglitazone on endothelial function, C-reactive protein, 
and components of the metabolic syndrome in nondiabetic 
patients with the metabolic syndrome. Am J Cardio. 2004; 
93: 362 – 365.
262. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 
1106 – 1118.
263. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, 
Cuzzocrea S, Pisano B, et al. Ligands of the peroxisome 
proliferator-activated receptors (PPAR-gamma and PPAR-
alpha) reduce myocardial infarct size. FASEB J 2002; 16: 
1027 – 1040.
264. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs 
glibenclamide on postprandial increases in glucose and TG 
levels and on oxidative stress in Japanese patients with 
type 2 diabetes. Endocrine 2006; 29: 143 – 148.
265. Campia U, Matuskey LA, Panza JA. Peroxisome 
proliferatoractivated receptor-gamma activation with 
pioglitazone improves endothelium-dependent dilation in 
nondiabetic patients with major cardiovascular risk factors. 
Circulation 2006; 113: 867 – 875.
266. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on 
endothelial function, insulin sensitivity, and glucose control 
in subjects with coronary artery disease and new-onset type 
2 diabetes. Diabetes Care 2006; 29: 1039 – 1045.
267. Ceriello A. Thiazolidinediones As Anti – inﬂammatory and Anti 
– Atherogenic Agents. Diabetes Metab Res Rev 2008; 24: 
14 – 26.
268. Goldﬁne AB. The Rough Road for Rosglitazone. Curr Opin 
Endocrinol Metab 2008; 15: 113 – 117.
269. Home PD, Phil D, Pocock SJ, Beck – Nielsen H, Gornis R, 
Hanefeld M, Jones NP, Komadja M, McMurray JJV. 
Rosglitazone Evaluated for Cardiovascular Outcomes – An 
Interim Analysis. N Engl J med 2007; 357: 28 – 38.
270. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-
study. High-density lipoprotein and coronary heart-disease: 
a prospective case-control study. Lance 1977;  1: 965 
– 968.
271. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein 
cholesterol and mortality. The Framingham Heart Study. 
Arteriosclerosis 1988; 8: 737 – 741.
272. Benoit P, Emmanuel F, Caillaud JM, bassinet L, Castro G, Gallix 
P, et al. Somatic gene transfer of human ApoA-I inhibits 
atherosclerosis progression in mouse models. Circulation 
1999; 99: 105 – 110.
 ͵ͳ
PPARs and the metabolic syndrome (Meiliana A, et al.)
Indones  Biomed J. 2009; 1(1): 4-31DOI: 10.18585/inabj.v1i1.79
273. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, 
Lestavel S , et a l. R educed cholesterol absorption upon 
PPARdelta activation coincides w ith decreased i ntestinal 
expression of NPC1L1. J. Lipid Res 2005; 46: 526 – 534.
274. S taels B, F ruchart JC. Therapeutic R oles o f Peroxisome 
Proliferator—Activated R eceptor A gonist. Diabetes 2005; 
54: 2460 – 2470.
275. C arr DB, Utzschneider K M, H ull RL, Kodama K, R etzlaff 
BM, Brunzell JD, et a l. I ntra-abdominal f at i s a major 
determinant of the National Cholesterol Education Program 
Adult Treatment Panel III criteria for the metabolic syndrome. 
Diabetes 2004; 53: 2087 – 2094.
276. [ Anonymous]. Clinical guidelines o n the identiﬁcation, 
evaluation, and treatment o f overweight and obesity i n 
adults: the evidence r eport. N ational I nstitutes o f Health. 
Obes Res 1988; 6(Suppl. 2): 51S – 209S.
277. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 
591 – 602. 
278. Lee CH, et al. PPAR delta is a potent insulin sensitizer. Proc 
Natl Acad Sci USA 2006; in press.
279. F lévet C , Fruchart JC, Staels B. P PAR  and P PAR  D ual 
Agonists for The Treatment o f Type 2  D iabetes and The 
Metabolic Syndrome. Curr Opin Pharmacol 2006; 6: 606.
280. Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L, et 
al. Muraglitazar, a Novel Dual ( / ) Peroxisome Proliferator–
Activated Receptor Activator, Improves Diabetes and Other 
Metabolic Abnormalities and P reserves -Cell Function in 
db/db Mice. Diabetes 2006; 55: 240 – 248.
281. Fagerberg B, E dward S, Halmos T, Lopatynsky J , Schuster 
H, Stender S, et al. Tesaglitazar, a Novel Dual Peroxisome 
Proliferator –  A ctivated R eceptor /  A gonist, Dose 
– Dependently I mproves t he M etabolic A bnormalities 
Associated W ith Insulin R esistance i n A Non – Diabetic 
Population. Diabetologia 2005; 48: 1716 – 1725.
282. Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH. Therapeutic 
Potential of Peroxisome Proliferator – Activated Receptor - 
/  Dual Agonist With Alleviation of Endoplasmic Reticulum 
Stress f or t he Treatment o f Diabetes. D iabetes 2008; 57: 
737 – 745.
